



15th ANNUAL REPORT 2025-2026



CORPORATE INFORMATION
Global Longlife Hospital and Research Limited
CIN: L85110GJ2012PLC068700

Board of Directors

Name	Designation
Mr. Dhruv Jani	Managing Director
Ms. Sucheta Jani	Non-Executive Director
Ms. Hetal Thakkar	Executive Director
*Mr. Sandeep Shah	Independent Director
Mr. Manasvi Thapar	Independent Director
*Mr. Hiren Mandaliya	Additional Director (Independent Director)

*Mr. Hiren Mandaliya was appointed as an Additional Director of the Company with effect from March 31, 2026. Mr. Sandeep Shah resigned from the company with effect from December 08, 2025.

Key Managerial Personnel

Ms. Hetal Thakkar	Chief Financial officer
Ms. Tanvi Solanki	Company Secretary and Compliance Officer

STATUTORY AUDITOR

M/s. R.B. Gohil & Co., Chartered Accountants

Address: 1st Floor, K.P. Shah House-2, K.V. Road, Jamnagar – 361001, Gujarat, India.

Tel No.: +91 9426478227

Email: rbgohil.gj@gmail.com

SECRETARIAL AUDITOR

M/s. Insiya Nalawala & Associates, Company Secretaries

Address: A/84, Pariseema Complex, Opp. Tanishq, C G Road, Ahmedabad – 380 009, Gujarat, India

Tel No.: +91-9724509467

Email: insiya@csinsiya.in

REGISTRAR & SHARE TRANSFER AGENT

BIGSHARE SERVICES PRIVATE LIMITED

Address: E-3 Ansa Industrial Estate Saki Vihar Road Sakinaka Mumbai – 400 072, Maharashtra, India

Tel No. 079-49196459

Email: bssahd@bigshareonline.com

BANKERS TO THE COMPANY

The Kalupur Commercial Co-op. Bank Limited

Address: SME MID Corporate Branch, Annexe Building, Kalupur Bank Bhavan, Nr. Income Tax Circle, Ashram Road, Ahmedabad - 380014

Tel: 079- 2758 2026

Fax No.: 079- 2754 4450

Email id: midcrop@kalupurbank.com

REGISTERED OFFICE

703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road,
 Ahmedabad – 380 059, Gujarat, India

Tel No.: +91-7211104280

Email: investor@globalhospital.co.in; **Website:** www.globalhospital.co.in;

COMMITTEES OF BOARD

1. AUDIT COMMITTEE COMPOSITION#

Name of the Director	Designation	Nature of Directorship
Mr. Hiren Mandaliya	Chairman	Independent Director
Mr. Manasvi Manu Thapar	Member	Independent Director
Mr. Dhruv Suresh Jani	Member	Managing Director

2. NOMINATION AND REMUNERATION COMMITTEE COMPOSITION#

Name of the Director	Designation	Nature of Directorship
Mr. Manasvi Manu Thapar	Chairman	Independent Director
Mr. Hiren Mandaliya	Member	Independent Director
Mrs. Sucheta Dhruv Jani	Member	Non-Executive Director

3. STAKEHOLDERS RELATIONSHIP COMMITTEE COMPOSITION#

Name of the Director	Designation	Nature of Directorship
Mr. Manasvi Manu Thapar	Chairman	Independent Director
Mr. Hiren Mandaliya	Member	Independent Director
Mrs. Sucheta Dhruv Jani	Member	Non-Executive Director

#The above Committee were reconstituted w.e.f. March 31, 2026 and Mr. Hiren Mandaliya was appointed as Chairman of Audit committee and Member of Nomination and remuneration committee and Stakeholders Relationship committee of the committee.

NOTICE OF 15th ANNUAL GENERAL MEETING

NOTICE is hereby given that the 15th (Fifteen) Annual General Meeting of the members of Global Longlife Hospital and Research Limited (CIN: L85110GJ2012PLC068700) will be held on Thursday, June 25, 2026 at 11:00 A.M. IST through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”) to transact the following businesses:

Ordinary Business:

- 1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2026 and the Report of the Board of Directors and Auditors thereon.**
- 2. To appoint a director in place of Ms. Sucheta Jani (DIN: 06502321), who retires by rotation and, being eligible, offers herself for re-appointment.**

Special Business:

- 3. Appointment/ Regularization of Mr. Hiren Mandaliya (DIN: 11636452) as an Independent Director of the company for a first term of five consecutive years**

To consider and if, thought fit, to pass with or without modification the following resolution as **Special Resolution:**

“RESOLVED THAT pursuant to provision of Section 149, 150, 152, 161 read with Schedule IV, and any other applicable provisions of the Companies Act, 2013, if any, read with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and applicable regulation of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Mr. Hiren Mandaliya (DIN: 11636452) who was appointed as an Additional Director of the Company w.e.f. March 31, 2026 by the Board of Directors of the company based on the recommendation of Nomination and Remuneration Committee in their meeting held on March 31, 2026, and who holds office up to the date of this Annual General Meeting and who also meets the criteria for independence as provided in Section 149(6) of the Act along with the rules framed thereunder and Regulation 16(1) of the Listing Regulations and who have submitted a declaration to that effect and in respect of whom the company has received a notice in writing form a Member under Section 160 of Act proposing his candidature for the office of Director of the Company, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a first term of Five consecutive years effective from March 31, 2026 to March 30, 2031 on the board of the company.

RESOLVED FURTHER THAT pursuant to the provision of Section 197(5) of the Companies Act, 2013 (“Act”) read with rules framed thereunder and Schedule IV of the Act and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof), applicable clauses of the Articles of Association of the Company and recommendation of the Nomination and Remuneration Committee, the approval of shareholders of the company is hereby accorded that the sitting fees payable to Mr. Hiren Mandaliya, Independent Director of the company will be upto Rs. 1,00,000/- per annum for attending the board meetings, committee meetings and general meetings of the company during his tenure as Independent Director of the company with effect from March 31, 2026.

RESOLVED FURTHER THAT any Directors and/or Company Secretary of the Company be and are hereby severally authorized to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this Resolution.”

4. Approval of Change in the Name of the Company and consequent Amendment of Memorandum of Association and Articles of Association of the company

To consider and if, thought fit, to pass with or without modification the following resolution as **Special Resolution:**

“**RESOLVED THAT** pursuant to the provisions of Sections 4, 5, 13, 14 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Incorporation) Rules, 2014 and other applicable rules framed thereunder, applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, subject to approval of the Central Registration Centre/Registrar of Companies, Stock Exchanges and such other statutory and regulatory authorities as may be required, consent of the Shareholders of the Company be and is hereby accorded for change in the name of the Company from “GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED” to KANZI ENTERPRISE LIMITED OR ASAHI ENTERPRISE LIMITED OR SIDDHAA ENTERPRISE LIMITED or any other name as may be made available and approved by the concerned authorities.

RESOLVED FURTHER THAT upon approval of the proposed new name by the statutory authorities, Clause I of the Memorandum of Association and relevant provisions of the Articles of Association of the Company be and are hereby altered accordingly.

RESOLVED FURTHER THAT any Director and/or Company Secretary of the Company, be and are hereby severally authorized to:

1. make application for reservation and approval of the proposed name with the Central Registration Centre/Registrar of Companies;
2. file necessary forms, applications, returns and documents with the Registrar of Companies, Stock Exchanges, SEBI and any other statutory/regulatory authority;
3. sign and execute all documents, declarations, undertakings, affidavits and writings as may be necessary;
4. appoint professionals/consultants, if required, in connection with the aforesaid matter; and
5. do all such acts, deeds, matters and things as may be deemed necessary, proper or expedient for giving effect to this resolution.

RESOLVED FURTHER THAT any Directors and/or Company Secretary of the Company be and are hereby severally authorized to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this Resolution.”

5. Alteration of Object clause of the Memorandum of Association of the company

To consider and if, thought fit, to pass with or without modification the following resolution as **Special Resolution:**

“RESOLVED THAT pursuant to the provisions of Section 13 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Incorporation) Rules, 2014, the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and subject to such other approvals, permissions and sanctions as may be necessary, consent of the Shareholders of the Company be and is hereby accorded for alteration of Clause III(A) of the Memorandum of Association of the Company by inserting/substituting the following new object clause:

1. To carry on the business in India or elsewhere to manufacture, produce, process, prepare, crush, refine, blend, filter, deodorize, disintegrate, clean, sort, recover, amalgamate, mix, convert, purify, commercialize, grade, compound, pack, re-pack, disinfect, derive, excavate, explore and extract, import, export, buy, sell, turn to account to acts as agent, broker, stockiest, dealers, distributors, retailer, wholesaler, merchant, trader, supplier, packer, C & F Agent, representative, consignor, job worker, manufacturer’s representative, franchiser, collaborator, concessionaries, consultants, advisor, or otherwise to deal in all kind of foods, spices, agriculture produces, commodities, products, items, goods, crops, trees, plants, leaves, herbs, grains, food grains, cereals, pulses, spices, flours, rice, wheat, ground nuts, seed, agro seeds, soyabeans, castors, mustard, maize, Bajara, cotton, sesame, sesame seeds, oilseeds, edible oils, flowers, vegetables, fruits and food products.
2. To carry on the business of buyers, sellers, exporters, importers, merchandisers, traders, coordinators, distributors, agents, brokers, stockists, commission agents, auctioneers, dealers, concessionaires, contractors, packers, processors, texturizers, retailers, wholesalers, suppliers, in India and abroad of all kinds of apparels, dresses, clothes, outfits, garments, textiles, fabrics, yarns, fibbers, silk, cotton, hemp, jute, linen, fibbers, linen, plastics, rubbers, canvas goods, dealing in commodity exchange , book goods on commodity market, Bullion market, purchase and sales of Gold, Silver and other precious metal in physical form or on metal exchange, do trade in other lease on agriculture land & organic farming and allied products, all types of fibers, synthetic artificial & natural fibers, nylon, rayon, textiles substance allied product, by-products and substitutes for all or any of them and thereof.

RESOLVED FURTHER THAT the existing Clause III(A) of the Memorandum of Association of the Company be and is hereby altered accordingly.

RESOLVED FURTHER THAT any director and/or Company Secretary of the Company, be and are hereby severally authorized to file necessary e-forms with the Registrar of Companies and Stock Exchange(s), and to do all such acts, deeds, matters and things as may be deemed necessary, proper or expedient for giving effect to this resolution, including making necessary alterations, modifications or corrections as may be required by any statutory or regulatory authority.”

6. Re-appointment of Mr. Dhruv Jani (DIN: 03154680) as Managing Director of the company for the period of five consecutive years.

To consider and if, thought fit, pass with or without modification the following resolution as an **Special Resolution:**

“RESOLVED THAT pursuant to the provisions of Section 196, Section 197 and section 203 read with Schedule V and any other applicable provisions of the Companies Act, 2013 (“Act”) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification (s) thereto or re-enactment thereof for the time being in force) and pursuant to Articles of Association of the company and subject to such other approvals, permissions and sanctions, as may be required and subject to such conditions and modifications, as may be prescribed or imposed by any of the authorities while granting such approvals, permissions and sanctions, the consent of the shareholders of the company be and is hereby accorded for re-appointment of Mr. Dhruv Jani (DIN: 03154680), as the Managing Director of the Company, for a period of 5 years with effect from September 10, 2026 to September 09, 2031, liable to retire by rotation, on a basic salary of upto Rs. 36,00,000/- per annum (Thirty Six Lakhs) and on such terms and conditions as set out in the foregoing resolution and explanatory statement annexed thereto.

RESOLVED FURTHER THAT the terms and remuneration as set out in the explanatory statement of this resolution shall be deemed to form part hereof and in the event of inadequacy or absence of profits, till the tenure of his term, the remuneration comprising salary, perquisites, incentives, and all other benefits approved by the Board of Directors be paid as minimum remuneration to the Managing Director.

RESOLVED FURTHER THAT such remuneration payable to Mr. Dhruv Jani may exceed five percent of the net profits of the Company in any financial years and that the aggregate remuneration payable to him as well as other Executive Director of the Company may exceed ten percent of the net profits of the Company in any of the financial year and the overall remuneration to all the directors may exceed eleven percent of the net profits of the Company calculated under Section 198 of the Companies Act, 2013 in any of the financial years.

RESOLVED FURTHER THAT any Director, and/or Company Secretary of the Company, be and is hereby authorized to do all acts, deeds, things, matters and take all such steps as may be necessary, proper or expedient to give effect to the foregoing resolution.

7. Re-appointment of Mr. Manasvi Manu Thapar (DIN: 07486932) as an Independent Director of the Company for Second term of five consecutive years

To consider and if, thought fit, to pass with or without modification the following resolution as **Special Resolution:**

“RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, read with Schedule IV and any other applicable provisions, if any, of the Companies Act, 2013 (“Act”) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modifications or re-enactment(s) thereof for the time being in force), Mr. Manasvi Manu Thapar, (DIN: 07486932) who was appointed as an Independent Director of the Company, and who holds position as an independent director up to September 09, 2026 and who also meets the criteria for independence as provided in Section 149(6) of the Act along with the rule framed thereunder and Regulation 16(1) of the Listing Regulations and who have submitted a declaration to that effect and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing his candidature for Company, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of Five consecutive years w.e.f. September 10, 2026 upto September 09, 2031.

RESOLVED FURTHER THAT pursuant to the provision of Section 197(5) of the Companies Act, 2013 (“Act”) read with rules framed thereunder and Schedule IV of the Act and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof), applicable clauses of the Articles of Association of the Company and recommendation of the Nomination and Remuneration Committee, the approval of shareholders of the company is hereby accorded that the sitting fees payable to Mr. Manasvi Thapar, Independent Director of the company will be upto Rs. 1,00,000/- per annum for attending the board meetings, committee meetings and general meetings of the company during his tenure as Independent Director of the company.

RESOLVED FURTHER THAT any Director, and/or Company Secretary of the Company be and are hereby authorized to do all acts and take such steps as may be necessary, proper or expedient to give effect to this Resolution.”

EXPLANATORY STATEMENT UNDER SECTION 102 OF THE COMPANIES ACT, 2013

(Pursuant to Section 102 (1) of the Companies Act 2013 and Secretarial Standard 2 on General Meetings)

ITEM NO. 03

Appointment of Mr. Hiren Mandaliya (DIN: 11636452) as an independent director of the company for a first term of five consecutive years

Pursuant to the provisions of Section 161 of the Companies Act, 2013 (the 'Act'), the Board of Directors of the Company based on the recommendation of the Nomination and Remuneration Committee, appointed Mr. Hiren Mandaliya (DIN: 11636452) as an Additional Director in the capacity of a Non-Executive Independent Director with effect from March 31, 2026, at its meeting held on March 31, 2026, for a first term of 5 (Five) year, not liable to retire by rotation, subject to the approval of Members of the Company by way of a Special Resolution In terms of Section 161(1) of the Companies Act, 2013, he holds office only up to the date of the ensuing Annual General Meeting ('AGM') but he is eligible for appointment as an Independent Director, whose office shall not be liable to retire by rotation. The Company has in terms of Section 160(1) of the Companies Act, 2013 received a notice in writing from a Member proposing his candidature for the office of Independent Director of the Company. Mr. Hiren Mandaliya has given a declaration to the Board that he meets the criteria of Independence as provided under Section 149(6) of the Act.

Mr. Hiren Mandaliya is a Fellow Member of The Institute of Chartered Accountants of India and practicing as Chartered Accountant. He is a partner of M/s. A H Mandaliya & Associates, Chartered Accountants. He is having more than 10 years of experience in the area of Direct and Indirect Taxation, Auditing, Corporate Restructuring and Financial Modelling. Further, He possesses relevant expertise and experience and fulfils the conditions specified in the Companies Act, 2013 and the rules made thereunder and he is independent from the management.

The Company has received the following declaration from Mr. Hiren Mandaliya:

- (i) Consent in writing to act as Director in Form DIR-2 pursuant to Rule 8 of Companies (Appointment and Qualification of Directors) Rules, 2014
- (ii) Intimation in form DIR-8 in terms of Companies (Appointment and Qualification of Directors) Rules, 2014, to the effect that she is not disqualified under section 164(2) of the Companies Act, 2013 and
- (iii) Declaration to the effect that he meets the criteria of independence as provided in section 149 (6) of the Companies Act, 2013 read with Regulation 16(1) and Regulation 25(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and
- (iv) Declaration pursuant to BSE circular No. LIST/ COMP/14/2018-19 dated June 20, 2018 that he is not been debarred from holding office of director by virtue of any order passed by Securities and Exchange Board of India or any other such authority.

Brief resume and other details of Mr. Hiren Mandaliya whose appointment is proposed hereby provided in the annexure to the Explanatory Statement attached herewith. The Board considers that his continuous association would be of immense benefit to the Company and it is desirable to continue to

avail services of Mr. Hiren Mandaliya as an Independent Director. The terms and conditions of appointment of Mr. Hiren Mandaliya shall be open for inspection through electronic mode.

In compliance with the provisions of Section 149 read with Schedule IV of the Act, the appointment of Mr. Hiren Mandaliya as Independent Director is now being placed before the Members for their approval.

Save and except Mr. Hiren Mandaliya, none of the other directors / Key Managerial Personnel's of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution.

The Board recommends the Resolution set out in Item No. 2 of the Notice for approval by the shareholders as a Special Resolution.

ITEM NO. 4

Approval of Change in the Name of the Company and consequent Amendment of Memorandum of Association and Articles of Association of the company

The Board of Directors of Global Longlife Hospital and Research Limited at its meeting held on May 07, 2026, subject to the approval of the Members and other regulatory/statutory authorities, approved the proposal for change of name of the Company from "GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED" to "KANZI ENTERPRISE LIMITED" or "ASAHI ENTERPRISE LIMITED" or "SIDDHAA ENTERPRISE LIMITED" or such other name as may be approved and made available by the Registrar of Companies, Ministry of Corporate Affairs and other concerned authorities.

The proposed change of name is being undertaken to reflect the proposed diversification/repositioning of the business activities of the Company and to align the name of the Company with its future business plans, vision, branding and corporate identity. The Board believes that the proposed new name would better represent the activities and growth strategy of the Company.

The change of name of the Company, if approved by the Members and the Central Registration Centre/Registrar of Companies and other applicable authorities, will not affect any rights or obligations of the Company or the Members of the Company. The change of name will not result in any change in the constitution of the Company, share capital, management or existing business operations of the Company. All existing contracts, agreements, licenses, approvals, rights, obligations and liabilities of the Company shall continue under the new name.

Pursuant to the provisions of Sections 4, 5, 13, 14 and other applicable provisions, if any, of the Companies Act, 2013 read with the applicable Rules made thereunder, approval of the Members by way of a Special Resolution is required for change of name of the Company and consequential alteration in Clause I of the Memorandum of Association and Articles of Association of the Company. Accordingly, Clause I of the Memorandum of Association of the Company and the relevant provisions of the Articles of Association of the Company shall be substituted with the new name of the Company as approved by the Registrar of Companies and other regulatory authorities.

The Board of Directors recommends the Special Resolution set out at Item No. 4 of the accompanying Notice for approval of the Members of the Company.

None of the Directors, Key Managerial Personnel of the Company and their relatives are, in any way, concerned or interested, financially or otherwise, in the proposed resolution except to the extent of their shareholding, if any, in the Company.

ITEM NO. 5

Alteration of Object Clause of the Memorandum of Association of the company

The Company is presently engaged in the business activities as set out in the existing Object Clause of the Memorandum of Association (“MOA”) of the Company. In order to expand/diversify the business operations of the Company and to enable the Company to undertake additional business activities which can be carried out conveniently along with the existing business activities, the Board of Directors of the Company at its meeting held on May 07, 2026, subject to approval of the shareholders and other statutory/regulatory approvals, if any, approved alteration of Clause III(A) of the Memorandum of Association of the Company.

The proposed alteration in the Object Clause is intended to align the business activities of the Company with its future growth plans and business opportunities. The alteration would enable the Company to carry on the proposed business activities more efficiently and economically.

Accordingly, it is proposed to alter Clause III(A) of the Memorandum of Association of the Company by inserting the following new clause(s):

1. To carry on the business in India or elsewhere to manufacture, produce, process, prepare, crush, refine, blend, filter, deodorize, disintegrate, clean, sort, recover, amalgamate, mix, convert, purify, commercialize, grade, compound, pack, re-pack, disinfect, derive, excavate, explore and extract, import, export, buy, sell, turn to account to acts as agent, broker, stockiest, dealers, distributors, retailer, wholesaler, merchant, trader, supplier, packer, C & F Agent, representative, consignor, job worker, manufacturer’s representative, franchiser, collaborator, concessionaries, consultants, advisor, or otherwise to deal in all kind of foods, spices, agriculture produces, commodities, products, items, goods, crops, trees, plants, leaves, herbs, grains, food grains, cereals, pulses, spices, flours, rice, wheat, ground nuts, seed, agro seeds, soyabeans, castors, mustard, maize, Bajara, cotton, sesame, sesame seeds, oilseeds, edible oils, flowers, vegetables, fruits and food products.
2. To carry on the business of buyers, sellers, exporters, importers, merchandisers, traders, coordinators, distributors, agents, brokers, stockists, commission agents, auctioneers, dealers, concessionaires, contractors, packers, processors, texturizers, retailers, wholesalers, suppliers, in India and abroad of all kinds of apparels, dresses, clothes, outfits, garments, textiles, fabrics, yarns, fibbers, silk, cotton, hemp, jute, linen, fibbers, linen, plastics, rubbers, canvas goods, dealing in commodity exchange , book goods on commodity market, Bullion market, purchase and sales of Gold, Silver and other precious metal in physical form or on metal exchange, do trade in other lease on agriculture land & organic farming and allied products, all types of fibers, synthetic artificial & natural fibers, nylon, rayon, textiles substance allied product, by-products and substitutes for all or any of them and thereof.

Pursuant to the provisions of Sections 4, 13 and other applicable provisions, if any, of the Companies Act, 2013 read with applicable rules made thereunder, alteration of the Object Clause of the Memorandum of Association requires approval of the shareholders of the Company by way of Special Resolution.

The draft amended Memorandum of Association of the Company containing the proposed alterations is available for inspection by the members at the Registered Office of the Company during business hours on all working days up to the date of the meeting and shall also be available during the meeting. None of the Directors, Key Managerial Personnel of the Company and/or their relatives are, in any way, concerned or interested, financially or otherwise, in the proposed resolution except to the extent of their shareholding, if any, in the Company.

The Board of Directors recommends the Special Resolution set out at Item No. 5 of the Notice for approval of the Members of the Company.

ITEM NO. 6

Re-appointment of Mr. Dhruv Jani (DIN: 03154680) as Managing Director of the company for the period of five consecutive years

The Members of the Company at the Annual General Meeting held on September 10, 2021, had appointed Mr. Dhruv Jani (DIN: 03154680) as Managing Director of the Company for a period of five years commencing September 10, 2021 and ending on September 09, 2026. Accordingly, his term as the Managing Director shall complete on September 09, 2026.

Profile of Mr. Dhruv Jani

Mr. Dhruv Jani is the Promoter and Managing Director of the Company. He has been appointed as Managing Director of our company w.e.f. September 10, 2021. He holds a Bachelor Degree of Business Administration from Gujarat University. He has experience of more than 10 years in the cotton and oil business. He is associated with our Company since 2015. He presently looks after finance, overall management and operation of the company. As the tenure of his appointment will expire on September 09, 2026, the Board of Directors in its meeting held on May 30, 2026 upon the recommendation of Nomination and Remuneration Committee reappointed him as Managing Director of the company, subject to the approval of members of the company in this Annual General Meeting, for further period of five years from September 10, 2026 to September 09, 2031.

The principal terms and conditions of re-appointment of Mr. Dhruv Jani including the terms of remuneration are given below:

1. Tenure of Appointment

The re-appointment of Mr. Dhruv Jani as Managing Director for a period of five (5) years i.e., from September 10, 2026 to September 09, 2031, liable to retire by rotation.

2. Nature of Duties

Mr. Dhruv Jani shall devote his whole time and attention to the business of the Company and carry out such duties as may be entrusted to him by Board, and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board, in connection with and in the best interests of the Company and the business of any one or more of its Associated Companies and/ or Group Companies, including performing duties as assigned by the Board from time to time by serving on the Boards of such Associated Companies/ Group Companies or any other Executive body or a Committee of such a

Company. Mr. Dhruv Jani undertakes to employ the best of his skill and ability to make his utmost endeavours to promote the interests and welfare of the Company and to conform to and comply with the directions and regulations of the Company and all such orders and directions as may be given to him from time to time by the Board.

3. Remuneration

Basic Salary not exceeding Rs. 36,00,000/- per annum (Thirty Six Lakhs).

Perquisites and Performance Pay: As stated in Resolution No. 06. Mr. Dhruv Jani is also entitled to grant of Stock Options, during his re-appointment, as may be decided by the company from time to time.

Apart from the above mentioned details, the below mentioned terms and conditions have been entered into between the Company and the Managing Director:

- a. The Managing Director is also required to adhere with the Code of Conduct, intellectual property, non-competition, no conflict of interest with the Company and maintenance of confidentiality.
 - b. The terms and conditions of the re-appointment of the Managing Director may be altered and varied from time to time by the Board as it may, in its discretion deem fit, irrespective of the limits stipulated under Schedule V to the Act or any amendments made hereafter in this regard in such manner as may be agreed to between the Board and the Appointee subject to such approvals as may be required.
 - c. This appointment may be terminated by giving one month notice on either side or the Company paying one month remuneration in lieu of such notice.
 - d. The Managing Director's appointment is by virtue of his employment in the Company and his appointment shall be subject to the provisions of Section 167 of the Act.
4. **Leave Benefit:** Leave with full pay & allowances and Encashment of leave not availed of shall be allowed as per Company's rules and it will not be considered in aggregate remuneration.
 5. **Reimbursement** of out of pocket expenses incurred, whether directly or indirectly, for the business of the Company will be done on actual basis.
 6. **Disclosure of Relationships Between Directors inter-se:** Ms. Sucheta Jani, Non-Executive Director is the wife of Mr. Dhruv Jani.
 7. Any other benefits, amenities and facilities not covered herein but authorized by the board of directors of the company shall be paid additionally.

The following additional information as required by Schedule V to the Companies Act, 2013 is given below:

I. General Information:

- (i) **Nature of Industry:** The Company is, inter alia, in the business of healthcare and hospital.
- (ii) **Date or expected date of commencement of commercial production:** The Company was incorporated on 2012 and started operations.
- (iii) **In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:** Not Applicable.
- (iv) **Financial performance based on given indicators – as per audited financial results for the year ended March 31, 2026:**

Particulars	Rupees (In Lakhs)
Gross Turnover & Income	0.52
Net Profit as per Statement of Profit & Loss (After Tax)	(171.95)
Computation of Net Profit in accordance with Section 198 of the Companies Act, 2013	(171.95)
Net Worth	2374.93

- (v) **Foreign investments or collaborators, if any:** Not Applicable

II. Information about the appointee:

- (i) **Background details:** Refer profile Section on item 6 in the explanatory statement.
- (ii) **Past remuneration during the financial year ended 31st March, 2026:** Rs. 12.00 lakhs
- (iii) **Recognition or awards:** Refer profile Section on item 6 in the explanatory statement.
- (iv) **Job Profile and his suitability:** Refer proposal Section stated above.
- (v) **Remuneration proposed:** Basic Salary of Rs. 36,00,000/- (Rupees Thirty Six Lakhs) per annum.
- (vi) **Perquisites and Performance Pay:** As stated in Resolution No. 06. Mr. Dhruv Jani is also entitled to grant of Stock Options, during his re-appointment, as may be decided by the company from time to time.
- (vii) **Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin):** Taking into consideration the size of the Company, the profile of Mr. Dhruv Jani, the responsibilities shouldered by him, future growth in turnover and profits of the Company and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration packages paid to similar senior level counterpart(s) in other companies.

- (viii) **Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:** Besides the remuneration proposed to be paid to him does not have any other pecuniary relationship with the Company or relationship with the managerial personnel.

III. Other Information:

- (i) Reasons of loss or inadequate profits: Decrease in turnover during the financial year 2025-2026.
- (ii) Steps taken or proposed to be taken for improvement and Expected increase in productivity and profits in measurable terms: Company is planning to change its object and name and proposed to do new line of business.

Mr. Dhruv Jani satisfies all the conditions set out in Part-I of Schedule V to the Act as also conditions set out under sub-section 3 of section 196 of the Act for being eligible for his re-appointment. He is not disqualified from being appointed as a Director in terms of section 164 of the Act and has given his consent to act as a Director. He is not debarred from holding the office of Director pursuant to any Order issued by the Securities and Exchange Board of India (“SEBI”) or any other authority and has given all the necessary declarations and confirmation including his consent to be re-appointed as a Managing Director of the Company. Further, the Company has received a notice from a Member under Section 160 of the Act proposing the re-appointment of Mr. Dhruv Jani as the Managing Director.

The draft copy of Agreement to be entered into with Mr. Dhruv Jani by the Company containing the terms and Conditions of the said appointment and remuneration is available at the registered office of the Company. Member can inspect the copy of Draft agreement during the business hours of the Company on working days.

The Company has immensely benefited during Mr. Dhruv Jani tenure as Managing Director since September 2021. The Board is satisfied with the integrity, expertise, and experience (including the proficiency) of Mr Dhruv Jani who is being re-appointed at this AGM and accordingly, the Board recommend the resolution for his re-appointment as set out at Item No. 6 of the accompanying Notice, for approval by the Members of the Company as special resolution.

Except Mr. Dhruv Jani and Mrs. Sucheta Jani, Directors of the company and their relatives who are deemed to be concerned or interested in this Resolution, none of the other directors or Key Managerial Personnel of the company and their relatives are concerned or interested, Financial or otherwise, in this resolution.

ITEM NO. 7

Re-appointment of Mr. Manasvi Manu Thapar, DIN: 07486932 as an Independent Director of the Company for Second term of five consecutive years

The Members of the Company at the Annual General Meeting held on September 10, 2021, had appointed Mr. Manasvi Manu Thapar, DIN: 07486932 as Non-executive Independent Director of the Company for the first term of five years. His term was valid upto September 09, 2026. Accordingly his first term as an Independent Director completed on September 09, 2026.

As per Section 149(10) of the Act, an Independent Director shall hold office for a term of upto five consecutive years on the Board of a Company but shall be eligible for re-appointment on passing a Special Resolution by the Company for another term of upto five consecutive years on the Board of a Company.

The Board of Directors of the Company at its Meeting held on May 30, 2026, pursuant to the recommendation of the Nomination and Remuneration Committee (“NRC”), has approved the re-appointment of Mr. Manasvi Thapar (DIN: 07486932) as an Independent and Non-Executive Director of the Company for a second term of 5 (five) consecutive years commencing from September 10, 2026 to hold office up to September 09, 2031 not liable to retire by rotation (both days inclusive).

Process & Basis of Re-Appointment: The NRC evaluated profiles of various candidates as an Independent Director of the Company was reaching end of tenure in September 10, 2026. The NRC had identified skills, expertise and competencies required by the Board for the effective functioning of the Company. The process of shortlisting and selection of the Independent Director was carried out and concluded by NRC members who were Independent Directors and not considered interested in such proposal. After considering qualifications, skillsets, experience, independence, knowledge, ability to devote sufficient time, the NRC selected and recommended to the Board, the re-appointment of Mr. Manasvi Thapar as Independent Director of the Company.

In line with this strategic approach, the re-appointment of Mr. Manasvi Thapar reflects the Company’s commitment to long term sustainability and seamless leadership transitions. His appointment which is in line with the requirements of the Company Policy on “Appointment of Directors and Senior Management and Succession Planning for orderly succession to the Board and Senior Management” is a proactive stance which underscores the Company’s dedication to maintaining a dynamic and resilient board, poised to navigate challenges and seize opportunities on the horizon.

The Company has received a notice in writing from a Member under section 160 of the Act proposing the candidature of Mr. Manasvi Thapar for the office of Director of the Company. He is not disqualified from being appointed as Director in terms of section 164 of the Act and has given his consent to act as a Director. The Company has received declarations from Mr. Manasvi Thapar stating that he meets the criteria of independence as prescribed under sub-section (6) of section 149 of the Act and Listing Regulations. Mr. Manasvi Thapar is not debarred from holding the office of Director pursuant to any Order issued by the Securities and Exchange Board of India (SEBI) or any other authority. In the opinion of the Board, Mr. Manasvi Thapar, fulfils the conditions for re-appointment as Independent Director as specified in the Act and the Listing Regulations and is independent of the management.

The Board is of the view that Mr. Manasvi Thapar knowledge and experience will be of immense benefit and value to the Company and, therefore, recommends his re-appointment to the Members. A copy of the draft letter of appointment of Mr. Manasvi Thapar setting out terms and conditions of appointment is available for inspection by the Members in electronic form. The Articles of Association of the Company are available for inspection by the Members in electronic form.

Save and except Mr. Manasvi Thapar, and his relatives to the extent of their shareholding interest, if any, in the Company, none of the other Directors, Key Managerial Personnel (“KMP”) of the Company and their relatives are, in any way, concerned or interested, financially or otherwise, in the Resolution set out at Item No. 7 of the Notice.

Mr. Manasvi Thapar is not related to any other Director / KMP of the Company. The Board recommends the Special Resolution set out at Item No. 7 of the Notice for approval of the Members.

NOTES:

1. Pursuant to the General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, AGM shall be conducted through VC / OAVM.
2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting.
3. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as venue voting on the date of the AGM will be provided by NSDL.
6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.globalhospital.co.in. The Notice can also be accessed from the websites of the Stock Exchange i.e. BSE Limited at www.bseindia.com and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.
7. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time.

8. The relevant details as required under regulation 36(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meeting issued by the institute of Company Secretaries of India of the Person seeking appointment as Director under Item No. 2, 3, 6 and 7 of the Notice are also annexed.
9. In terms of the provisions of Section 152 of the Act, The Nomination and Remuneration Committee and the Board of Directors of the Company commend the re-appointment of Ms. Sucheta Jani as Non-Executive Director, Mr. Dhruv Jani as Managing Director, Mr. Manasvi Thapar as Non-Executive Independent Director and Appointment of Mr. Hiren Mandaliya, Independent Director of the Company at this Meeting.
10. The cut-off date of sending notice and annual report to the shareholders is Saturday, May 30, 2026.
11. Electronic copy of the Annual Report 2025-26 is being sent to those Members whose e-mail address is registered with the Company / Depositories for communication purpose, unless any Member has requested for a physical copy of the same. Members may note that this Annual Report will also be available on the Company's website at www.globalhospital.co.in.
12. Relevant documents referred to in the accompanying Notice are open for inspection by the members in electronic mode by requesting through email to the company at investor@globalhospital.co.in.
13. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.
14. The speaker shareholders are required to registered themselves with the company by writing e-mail to the company at investor@globalhospital.co.in on or before June 20, 2026. The speaker shareholder should note that the questions at the Annual General meeting are limit to one question only due to continuing the further proceeding of the AGM. For any further questions/queries the shareholder can write to the company at investor@globalhospital.co.in.
15. The Register of Member and Share Transfer Books of the company will remain close from June 18, 2026 to June 25, 2026 (both days inclusive) for the purpose of 15th AGM.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING ANNUAL GENERAL MEETING ARE AS UNDER:

The remote e-voting period begins on Monday, June 22, 2026 at 09:00 A.M. IST and ends on Wednesday, June 24, 2026 at 05:00 P.M. IST The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Thursday, June 18, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Thursday, June 18, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none">1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.2. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available

under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

- Shareholders/Members can also download NSDL Mobile App “**NSDL Speede**” facility by scanning the QR code mentioned below for seamless voting experience.

NSDL Mobile App is available on






Individual Shareholders holding securities in demat mode with CDSL

- Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password.
- After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers’ website directly.
- If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.
- Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication,

	user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
 - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

6. If you are unable to retrieve or have not received the “Initial password” or have forgotten your password:
 - a) Click on “**Forgot User Details/Password?**”(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) **Physical User Reset Password?**” (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to insiya@csinsiya.in with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their

Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "[Forgot User Details/Password?](#)" or "[Physical User Reset Password?](#)" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to Mr. Sachin Kaleriya at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to investor@globalhospital.co.in.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to investor@globalhospital.co.in. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are

otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of “VC/OAVM” placed under “**Join meeting**” menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at investor@globalhospital.co.in. The same will be replied by the company suitably.

Other Instructions:

- 1) Ms. Insiya Nalawala, Practicing Company Secretary, Proprietor of M/s. Insiya Nalawala & Associates, Company Secretaries (Membership No. FCS 13422), has been appointed as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.
- 2) The Scrutinizer shall, immediately after the conclusion of voting at the annual general meeting, first count the votes cast at the meeting, thereafter unblock the votes cast through remote-e-voting in the presence of at least two witnesses not in the employment of the Company and make, not later than Two working days from the conclusion of the meeting a consolidated Scrutinizer's Report of the total votes cast in favor or against, if any, forthwith to the Chairman or any of the Director or Company Secretary of the Company. The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.globalhospital.co.in, website of Stock Exchange i.e. BSE Limited at www.bseindia.com, and on the website of NSDL at www.evoting.nsdl.com, within forty eight hours of the passing of the resolutions at the 15th AGM of the Company to be held on June 25, 2026 and communicated to BSE Limited, where the shares of the Company are listed.

For and on behalf of the Board of Directors

Date: May 30, 2026

Place: Ahmedabad

Dhruv Jani
Managing Director
DIN: 03154680

Registered Office

703, Sankalp Square, 3B,
Beside Taj Skyline, Sindhu Bhavan Road,
Ahmedabad – 380 059, Gujarat, India

Corporate Identification Number: L85110GJ2012PLC068700

Website: www.globalhospital.co.in

Email: investor@globalhospital.co.in

ANNEXURE TO ITEM NO. 2, 3, 6 AND 7 OF THE NOTICE

Information as required under Regulation 36 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meeting issued by the Institute of Company Secretaries of India with respect to the Appointment / Re-appointment of Directors at the ensuing Annual General Meeting is as under:

Name of the Director	Ms. Sucheta Jani	Mr. Hiren Mandaliya	Mr. Dhruv Jani	Mr. Manasvi Thapar
Director Identification Number	06502321	11636452	03154680	07486932
Date of Birth	22/06/1992	06/10/1988	19/09/1988	July 20, 1991
Date of joining the Board	September 10, 2021	March 31, 2026	July 05, 2015	August 02, 2021
Qualification	Bachelor of Engineering in Information and Technology	Chartered Accountant	Bachelor Degree of Business Administration	B.A. L.L.B (Hons.) (five year Integrated Programme)
Nature of expertise in specific functional areas	Ms. Sucheta gives her valuable insight in Business Expansion Strategies and Strengthening the IT segment.	Mr. Hiren Mandaliya a qualified Chartered Accountant with strong expertise in Accounting and Taxation.	He presently looks after finance, overall management and operation of the company.	He has his own professional practice as a Candour Legal firm and having 10 years of experience.
No. of Shares held in the Company	0.00	0.00	24,00,990	0.00
Directorship in listed company (Other than Global Longlife Hospital and Research Limited)	NA	NA	NA	City Pulse Multiventures Limited
Committee Memberships/ Chairmanship held in Listed Companies (Other than Global Longlife Hospital and Research Limited)	NA	NA	NA	Membership in Audit committee, Nomination and remuneration committee and Stakeholder Relationship Committee
Disclosure of relationships between Directors inter-se	Ms. Sucheta Dhruvkumar Jani is the wife of Mr. Dhruvkumar Jani	NA	Ms. Sucheta Dhruvkumar Jani is the wife of Mr. Dhruvkumar Jani	NA

For other details such as the number of meetings of the board attended during the year, remuneration drawn and relationship with other directors and key managerial personnel in respect of above directors, please refer to the Board Report which is a part of this Annual Report.

BOARD'S REPORT

To,
The Members,

Your Directors are pleased to present the 15th Board of Directors Report of Global Longlife Hospital and Research Limited (“the Company”) together with the Audited Financial Statements for the year ended March 31, 2026.

FINANCIAL SUMMARY AND HIGHLIGHTS

The financial performance for the year ended March 31, 2026 is summarized below:

Particulars	(Rupees in Lakhs)	
	2025-2026	2024-2025
Revenue from Operations	0.00	57.73
Other Income	0.52	501.61
Profit before Depreciation, Finance Costs, Exceptional Items and Tax Expense	(98.77)	85.73
Less: Depreciation/ Amortization/ Impairment	0.00	48.19
Profit before Finance Costs, Exceptional Items and Tax Expense	(98.77)	37.54
Less: Financial Costs	0.03	27.62
Profit before Exceptional Items and Tax Expense	(98.80)	9.92
Add/(less): Exceptional items	0.00	0
Profit before Tax Expense	(98.80)	9.92
Less: Tax Expense (Current & Deferred)	0.00	(9.95)
Excess/Short Provisions of earlier years	(73.15)	0.00
Profit for the year (1)	(171.95)	19.87
Total Comprehensive Income/loss (2)	0.00	0.00
Total (1+2)	(171.95)	19.87
Earning Per Share	(1.64)	0.19

Net revenue from operations stands Nil as against ₹ 57.73 Lakhs in the previous year. Other income stands at Rs. ₹ Lakhs in current year as compared to ₹ 501.61 Lakhs in previous year.

The Company incurred a loss of ₹ 171.95 Lakhs during the current financial year as against a Profit After Tax (PAT) of ₹19.87 Lakhs in the previous financial year.

Except as stated above, there are no material changes and commitments affecting the financial position of the Company, which have occurred between the end of the financial year 2025-2026 and the date of this Report.

TRANSFER TO RESERVES

The Board of Directors of your company has decided not to transfer any amount to the Reserves for the year under review.

DIVIDEND

With a view to conserve the resources for future prospects of the Company, your directors regret to declare dividend for the financial year 2025-26.

MAJOR EVENTS OCCURED DURING THE YEAR

During the Financial Year 2025-2026, the following major events were held:

1. Mr. Hiren Mandaliya (DIN: 11636452) was appointed as Additional Director (Non-Executive Independent Director of the company w.e.f. March 31, 2026.
2. Mr. Sandeep Shah (DIN: 01850151)), Independent Director of the company had resigned from the company with effect from December 08, 2025.

INDUSTRY OVERVIEW

Your Company is a Multi-Speciality Tertiary Care Hospital of Gujarat with well equipped for Medical & Surgical Specialities. As a policy any doctor having experience of more than 3 years can admit his patient in our hospital. We provide platform to the doctors for treatment of their patients.

Your Company has adopted the Standard Operating Procedures (SOPs) given by Ministry of Health & Family Welfare. Under the said SOPs every work function of our hospital is defined, every process is written down and every employee is trained in his/her duties as soon as he/she joins. Every equipment is maintained as per a predefined schedule. Every necessary license is obtained and renewed as required time to time.

Your Company is certified by National Accreditation Board for Hospitals and Healthcare Providers (“NABH Accredited”) which is committed to support improvement of quality of healthcare service in our country for all strata of the population through various methodologies and tools to supplement the efforts of the providers of healthcare service and the requirements of the system at various levels.

For further details with respect to overview of the industry and important changes in the industry during the last year, external environment and economic outlook please refer Management Discussion and Analysis Report which forms part of this Annual Report.

CAPITAL STRUCTURE

During the year, there were no changes in the Authorized share capital of the company. There were no changes in the paid-up share capital of the company and the details are as follow:

Authorized Capital

The Authorized Capital of the Company is ₹ 10,50,00,000/- divided into 1,05,00,000 Equity Shares of ₹ 10/- each.

Issued, Subscribed & Paid-up Capital

The Paid-up Capital of the Company as on March 31, 2026 was ₹10,50,00,000/- divided into 1,05,00,000 Equity Shares of ₹ 10/- each.

CREDIT RATING

During the period under review the company is not required to take credit rating.

INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

During the period under review the provisions relating to Investor Education and Protection Fund (IEPF) is not applicable to the company

DIRECTORS AND KEY MANAGERIAL PERSONNEL

The composition of the Board of Directors of the Company as on March 31, 2026 is as follows:

Sr. No.	Name of the Director	Category
1.	Mr. Dhruv Jani	Managing Director
2.	Mrs. Sucheta Jani	Non- Executive Director
3.	Ms. Hetal Thakkar	Executive Director
4.	Mr. Hiren Mandaliya	Additional Director Non- Executive Independent Director
5.	Mr. Manasvi Thapar	Non- Executive Independent Director

* Mr. Sandeep Shah (DIN: 01850151)), Independent Director of the company had resigned from the company with effect from December 08, 2025

Retirement by rotation and subsequent re-appointment:

Ms. Sucheta Jani (DIN: 06502321), Non-Executive Director, is liable to retire by rotation at the ensuing Annual General Meeting, pursuant to Section 152 and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and being eligible have offered herself for re-appointment.

Appropriate business for her re-appointment is being placed for the approval of the shareholders of the Company at the ensuing AGM. The brief resume of the Director and other related information has been detailed in the Notice convening the ensuing AGM of the Company.

Change in Board Composition

During the period under review, there were changes in the board composition.

- Mr. Hiren Mandaliya (DIN: 11636452) was appointed as Additional Director (Non-Executive Independent Director of the company w.e.f. March 31, 2026.
- Mr. Sandeep Shah (DIN: 01850151)), Independent Director of the company had resigned from the company with effect from December 08, 2025.

Changes in Board Composition after end of financial Year.

After the end of financial year 2025-26, there were no changes in the board composition.

Key Managerial Personnel

As per the provisions of Sections 2(51) and 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Mr. Dhruv Jani, Managing Director, Ms. Hetal Thakkar, Chief Financial Officer and Ms. Tanvi Solanki, Company Secretary, are the key managerial personnels of the Company.

DECLARATION BY INDEPENDENT DIRECTORS

All Independent Directors have submitted the declarations of Independence, as required under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI (LODR) Regulations, 2015 that they meet the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 as well as clause (b) of sub-regulation (1) of regulation 16 of the SEBI (LODR) Regulations, 2015 and that he/she is not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact his ability to discharge his duties with an objective independent judgment and without any external influence and that he is independent to management. The Independent directors have complied with the code for independent director as prescribed in schedule IV of the Companies Act, 2013 and code of conduct for the board of directors and senior management personnel of the company.

All the Independent Directors of the Company have enrolled their names in the online database of Independent Directors by Indian Institute of Corporate Affairs in terms of the recently introduced regulatory requirements. Also, the online proficiency self-assessment test as mandated will be undertaken by those Independent Directors of the Company who are not exempted within the prescribed timelines.

The company had formulated and implemented code of conduct for the board of directors and senior management personnel which is available on the Company's website: <https://globalhospital.co.in/wp-content/uploads/2021/11/Code-of-conduct.pdf>

NUMBER OF MEETINGS OF THE BOARD

The details of the meetings of Board of directors convened during the Financial Year 2025-26 are as follows:

The board of directors met 5 times during the Financial Year 2025-26. The meetings were held on April 28, 2025, July 23, 2025, November 12, 2025, December 08, 2025 and March 31, 2026.

BOARD COMMITTEES

There are various committees constituted as stipulated under the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 namely Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee.

1. AUDIT COMMITTEE

The Company has formed the Audit Committee vide resolution passed in the meeting of Board of Directors held on September 03, 2021 as per the applicable provisions of the Section 177 of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014 (as amended). The constituted Audit Committee comprises following members.

Name of the Director	Designation	Nature of Directorship
Mr. Hiren Mandaliya	Chairman	Independent Director
Mr. Manasvi Manu Thapar	Member	Independent Director
Mr. Dhruv Suresh Jani	Member	Managing Director

* Mr. Sandeep Shah (DIN: 01850151), Independent Director and Chairman of Audit committee of the company had resigned from the company with effect from December 08, 2025

The Company Secretary of our Company acts as a Secretary of the Audit Committee. The Chairman of the Audit Committee shall attend the Annual General Meeting of our Company to furnish clarifications to the shareholders in any matter relating to financial statements.

The powers, roles and terms of reference of the committee are in compliance with the Section 177 of the Companies Act, 2013 and rules made there under and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable.

The committee members met 4 times during the Financial Year 2025-26. The meetings were held on April 28, 2025, July 23, 2025, November 11, 2025 and March 31, 2026.

2. NOMINATION AND REMUNERATION COMMITTEE

The Company has formed the Nomination and Remuneration Committee as per Section 178 and other applicable provisions of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014 (as amended) vide board resolution dated September 03, 2021. The Nomination and Remuneration Committee comprises the following members:

Name of the Director	Designation	Nature of Directorship
Mr. Manasvi Manu Thapar	Chairman	Independent Director
Mr. Hiren Mandaliya	Member	Independent Director
Mrs. Sucheta Dhruv Jani	Member	Non-Executive Director

* Mr. Sandeep Shah (DIN: 01850151), Independent Director and Member of Nomination and Remuneration committee of the company had resigned from the company with effect from December 08, 2025

The Company Secretary of our Company acts as a Secretary to the Nomination and Remuneration Committee.

The roles and terms of reference of the committee are in compliance with the Section 178 of the Companies Act, 2013 and rules made there under and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable.

The committee members met 2 time during the Financial Year 2025-26. The meeting was held on July 23, 2025 and March 31, 2026.

3. STAKEHOLDERS' RELATIONSHIP COMMITTEE

Our Company has formed the Stakeholders Relationship Committee as per Section 178 and other applicable provisions of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014 (as amended) vide board resolution dated September 03, 2021. The constituted Stakeholders Relationship Committee comprises the following members:

Name of the Director	Designation	Nature of Directorship
Mr. Manasvi Manu Thapar	Chairman	Independent Director
Mr. Hiren Mandaliya	Member	Independent Director
Mrs. Sucheta Dhruv Jani	Member	Non-Executive Director

* Mr. Sandeep Shah (DIN: 01850151), Independent Director and Member of Stakeholders Relationship committee of the company had resigned from the company with effect from December 08, 2025

The Company Secretary of our Company is acting as a Secretary to the Stakeholders Relationship Committee.

The roles and terms of reference of the committee are in compliance with the Section 178 of the Companies Act, 2013 and rules made there under and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable.

The committee members met 1 time during the Financial Year 2025-26. The meeting was held on March 31, 2026.

AUDIT COMMITTEE RECOMMENDATIONS

During the year, all recommendations of Audit Committee were approved by the Board of Directors.

NOMINATION AND REMUNERATION POLICY

The Company has formulated and adopted the Nomination and Remuneration Policy in accordance with the provisions of Companies Act, 2013 read with the Rules framed thereunder and the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

The Nomination and Remuneration Committee have formulated the criteria for appointment of Executive, Non-Executive and Independent Directors on the Board of Directors of the Company and persons in the Senior Management of the Company, their remuneration including determination of qualifications, positive attributes, independence of Directors and other matters as provided under sub-section (3) of Section 178 of the Companies Act, 2013 (including any statutory modification(s) or reenactment(s) thereof for the time being in force).

The said policy is available on the Company's website at <https://globalhospital.co.in/policies-related-to-company>.

EVALUATION OF THE PERFORMANCE OF THE BOARD, COMMITTEES AND INDIVIDUAL DIRECTORS

Pursuant to the provisions of the Companies Act, 2013 read with Rules framed there under and in compliance with the requirements of SEBI (LODR) Regulations, 2015, the Board has carried out the annual evaluation of the performance of the Board as a whole, Individual Directors including Independent Directors, Non-Independent Directors, Chairperson and the Board Committees. A structured questionnaire was prepared after taking into consideration the inputs received from the Directors, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, Meetings of the board, functioning of the board, effectiveness of board processes, Board culture, execution and performance of specific duties, obligations and governance.

The exercise was also carried out to evaluate the performance of individual Directors including the Chairman of the Board, who were evaluated on parameters such as level of engagement and contribution, independence of judgment, safeguarding the interest of the Company and its minority shareholders etc.

The performance evaluation of the Independent Directors was carried out by the entire Board excluding the director being evaluated. The performance evaluation of the Chairman and the Non Independent Directors was carried out by the Independent Directors who also reviewed the performance of the Key Managerial Personnel. The Directors expressed their satisfaction with the evaluation process.

REMUNERATION OF DIRECTORS AND EMPLOYEES OF THE COMPANY

The information required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of Directors/employees of the Company is set out in “Annexure - [1]” of this report.

SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANY

During the period under review, your company do not have any subsidiary, joint venture and associate company.

DIRECTORS' RESPONSIBILITY STATEMENT

In terms of the requirements of Section 134(3)(c) read with Section 134(5) of the Companies Act, 2013, Board of Directors of the Company, hereby state and confirm that:

- a) in the preparation of the annual accounts for the financial year ended 31st March, 2026, the applicable accounting standards have been followed and there are no material departures from the same;
- b) they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of

affairs of the Company as at 31st March, 2026 and of the profit and loss of the Company for the financial year ended 31st March, 2026;

- c) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) they have prepared annual accounts on a going concern basis;
- e) they have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and operating effectively; and
- f) they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

INTERNAL FINANCIAL CONTROLS SYSTEMS AND THEIR ADEQUACY

The Board has adopted policies and procedure for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of fraud and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial disclosures.

During the year no reportable material weakness in the design or operation were observed.

FRAUDS REPORTED BY THE AUDITOR

The auditor of the Company has not reported any fraud to the Audit Committee or Board or to the Central Government under Section 143(12) of the Companies Act, 2013.

DISCLOSURES RELATING TO SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

During the period under review, your company do not have any subsidiary, joint venture and associate company.

PUBLIC DEPOSITS

During the year under review, Company has not accepted any deposit within the meaning of Sections 73 and 74 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014. Further, Company does not have any deposit which is in violation of Chapter V of the Act.

LOANS TAKEN FROM DIRECTORS OF THE COMPANY

During the year under review, Details of Unsecured Loans taken from Directors of the Company are given in the Notes to the Financial Statements forming part of Annual Report.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

The details of Loans, guarantee and Investments covered under the provisions of Section 186 of the Act are given in the Notes to the Financial Statements forming part of Annual Report.

RELATED PARTY TRANSACTIONS

During the FY 2025-26, Company has entered into some transactions with related parties as defined under Section 2(76) of the Companies Act, 2013, which were in the ordinary course of business and at arms' length basis. Further, the transactions were in accordance with the provisions of the Companies Act, 2013, read with rules framed thereunder and the SEBI (LODR) Regulations, 2015.

The details of the related party transactions as required under applicable accounting standard are set out in **Notes** to the financial statements.

The Company has formulated a policy on related party transactions, the same is available on Company's website at <https://globalhospital.co.in/wp-content/uploads/2021/11/Related-Party-Transaction-Policy.pdf>.

The detail disclosure of these transactions in Form Form AOC-2 pursuant to Section 134 (3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014 is set out as "**Annexure [2]**" to this Report.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

During the Financial Year 2025-26 the provision of Section 135 related to CSR is not applicable to the Company.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014.

Conservation of Energy

In its endeavour towards conservation of energy your Company ensure optimal use of energy, avoid wastages and conserve energy as far as possible.

Your company has started Solar power plant project of 250 KW i.e. 0.250 MW (AC) and 0.300 MW (DC) capacity at survey No. 476, Vilage Ranpura, Karanapura, Ta. Bechraji, Dist. Mehsana – 384 410 during the year and company will benefit approximately 40% on our yearly electricity consumption.

Technology Absorption

The Company has not carried out any research and development activities.

Foreign Exchange Earnings and Outgo

The Company had not made any transaction with any foreign country. Therefore, during the period under review there is no Foreign Exchange Earnings and Outgo.

RISK MANAGEMENT POLICY

The Company has a robust Risk Management policy. The Company through Board and Audit Committee oversees the Risk Management process including risk identification, impact assessment, effective implementation of the mitigation plans and risk reporting. Risk Management forms an integral part of the Company's planning process.

The Audit Committee has additional oversight in the area of financial risks and controls. Major risks identified by the business and functions are systematically addressed through mitigating actions on continuing basis.

There are no risks, which in the opinion of the Board threaten the existence of the Company.

VIGIL MECHANISM

Your Company has established a Vigil Mechanism/ Whistle Blower Policy which is in compliance with the provisions of Section 177(9) of the Companies Act, 2013 and Regulation 4(2)(d)(iv) read with Regulation 22 of the SEBI (LODR) Regulations, 2015. The policy enables stakeholders, including individual employees, directors and their representative bodies, to freely communicate their concerns about illegal or unethical practices, instances of unethical behaviour, actual or suspected fraud or violation of the company's code of conduct. The Policy provides adequate safeguards against victimization of Director(s)/ employee(s) and direct access to the Chairman of the Audit Committee in appropriate or exceptional cases. The Protected Disclosures, if any reported under this Policy will be appropriately and expeditiously investigated by the Chairman.

Your Company hereby affirms that no Director, employee or any other personnel has been denied access to the Chairman of the Audit Committee and that no complaint was received during the year.

The Whistle Blower Policy has been disclosed on the Company's website under the web link <https://globalhospital.co.in/wp-content/uploads/2021/11/Whistle-Blower-Policy.pdf> and circulated to all the Directors / employees.

SIGNIFICANT/MATERIAL ORDERS PASSED BY THE REGULATORS

There are no significant/material orders passed by the Regulators, Courts, Tribunals, Statutory and quasi-judicial body impacting the going concern status of the Company and its operations in future. The details of litigation on tax and other relevant matters are disclosed in the Auditors' Report and Financial Statements which forms part of this Annual Report.

AUDITORS

STATUTORY AUDITOR

In the 13th Annual General Meeting of the company held on September 27, 2024, the Shareholders of the Company had considered and approved the Re-Appointment of M/s. R. B. Gohil & Co., Chartered Accountants (Firm Registration No. 119360W), as Statutory Auditor of the company for the period of three years from conclusion of 13th AGM till the conclusion of 16th AGM (for Financial Year 2024-2025 to 2026-2027)

The Notes on financial statement referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report dated May 07, 2026, is unmodified and does not contain any qualification, reservation or adverse remark.

No fraud has been reported by the Auditors to the Audit Committee or the Board.

SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Director appointed Ms. Insiya Nalawala, proprietor of M/s Insiya Nalawala & Associates, Practising Company Secretary (Membership No. FCS 13422), to conduct the Secretarial Audit of the Company for the year ended March 31, 2026. The Secretarial Audit Report in prescribed Format Form MR-3 is annexed herewith as “**Annexure [3]**”.

INTERNAL AUDITOR

M/s. J J Patel & Associates, Chartered Accountants (FRN: 133005W) were appointed as the Internal Auditor of the company for the FY 2025-2026 by the Board of Directors of the Company in the Board Meeting held on July 23, 2025.

COMPLIANCE WITH SECRETARIAL STANDARD

The Company has complied with Secretarial Standards 1 and 2 issued by the Institute of Company Secretaries of India on Board meetings and General Meetings respectively.

CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC)

No corporate insolvency resolution process is initiated against the company under the IBC.

IMPLEMENTATION OF CORPORATE ACTION

During the year under review, the Company has not failed to implement any Corporate Actions within the specified time limit.

ANNUAL RETURN

Annual Return i.e. Form MGT-7 can be accessed on the Company's website at: www.globalhospital.co.in.

COST RECORDS AND COST AUDIT

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Act, are not applicable to the Company during the FY 2025-2026.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

As per requirements of SEBI (LODR) Regulations, 2015, a detailed review of the developments in the industry, performance of the Company, opportunities and risks, segment wise and product wise performance, internal control systems, outlook etc. of the Company is given under the head Management Discussion and Analysis Report, which forms part of this Annual Report.

CORPORATE GOVERNANCE REPORT

Your Company strives to incorporate the appropriate standards for corporate governance. However, pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is not required to mandatorily comply with the provisions of certain regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and therefore the Company has not provided a separate report on Corporate Governance, although few of the information are provided in this report of Directors under relevant heading.

DISCLOSURES AS PER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has adopted zero tolerance for sexual harassment at workplace and has formulated a policy on Prevention, Prohibition and Redressal of Sexual Harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules thereunder for prevention and Redressal of complaints of sexual harassment at workplace.

The policy aims to provide protection to employees at workplace and prevent and redress complaints of sexual harassment and for the matters connected and incidental thereto, with the objective of providing safe working environment, where employees feel secure.

An Internal Complaints Committee has been set up to Redress complaints related to sexual harassment. During the Financial year 2025-26, the company has not received any complaint of sexual harassment at workplace. Further, there was no complaint pending at the beginning of the year or at the end of the year. Company have complied with the provisions of the Sexual Harassment of Women at Workplace Act, 2013 to ensures a safe workplace for all employees.

MATERNITY BENEFIT ACT, 1961

During the Financial Year 2025-2026, the company is in compliance with the provisions of Maternity Benefit Act, 1961

WEBSITE

As per Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company has maintained a functional website namely “www.globalhospital.co.in” containing basic information about the Company. The website of the Company is containing information like Policies, Shareholding Pattern, Financial and information of the designated officials of the Company who are responsible for assisting and handling investor grievances for the benefit of all stakeholders of the Company.

ACKNOWLEDGEMENT

The Board wishes to place on record its sincere appreciation to the Company's customers, vendors, central and state government bodies, auditors, legal advisors, consultants, registrar and bankers for their continued support to the Company during the year under review. The Directors also wish to place on record their appreciation for the dedicated efforts of the employees at all levels. Finally, the Board expresses its gratitude to the members for their continued trust, co-operation and support.

For and on behalf of the Board of Directors

Date: May 30, 2026

Place: Ahmedabad

Dhruv Jani
Managing Director
DIN: 03154680

Sucheta Jani
Non-Executive Director
DIN: 06502321

Annexure [1] to Board's Report

Information required under Section 197 of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

A. Ratio of remuneration of each Director to the median remuneration of all the employees of the Company for the Financial Year 2025-2026 is as follows:

Name of Director	Designation	Total Annual Remuneration (Rs.)	Ratio of remuneration of director to the Median remuneration
Mr. Dhruv Jani	Managing Director	Rs. 12,00,000/-	8.33
Mrs. Sucheta Jani	Non-Executive Director	Rs. 6,00,000/-	4.16
Ms. Hetal Thakkar	Executive Director and CFO	-	

1. Independent Directors receiving only sitting fees for attending the board meeting. The sitting fees paid to Independent Directors is not covered in the above table.
2. Median remuneration of the Company for all its employees is Rs. 1,44,000/- per annum for the financial year 2025-2026.
3. The aforesaid details are calculated on the basis of remuneration for the financial year 2025-2026.

B. Details of percentage increase in the remuneration of each Director, Chief Executive Officer, Chief Financial Officer & Company Secretary in the financial year 2025-26 is as follows:

Name	Designation	Remuneration (in Rs.)		Increase (%)	Decrease (%)
		2025-2026	2024-2025		
Mr. Dhruv Jani	Managing Director	12,00,000	36,00,000	-	66.67%
Mrs. Sucheta Jani	Non-Executive Director	6,00,000	12,00,000	-	50%
Hetal Thakkar	CFO	-	7,32,000	-	100%
Tanvi Solanki	CS	1,44,000	1,44,000	-	-

Notes:

1. Independent directors receiving only sitting fees for attending the board meeting. So, in the above table, sitting fees paid to independent directors are not considered.
2. The remuneration to Directors is within the overall limits approved by the shareholders and as per Schedule V of the Companies Act, 2013.

C. Percentage increase in the median remuneration of all employees in the Financial Year 2025-2026: 80.33%.

D. Number of permanent employees on the rolls of the Company as on 31st March, 2026: 3

E. Comparison of average percentage increase in salary of employees other than the Managerial personnel and the percentage increase in the managerial remuneration:

Remuneration to Managerial Personnel (MD & WTD) is provided in point A of Annexure-1. While Average salary of all employees other than Managerial Personnel is increase by 87.73% in FY 2025-26 compared to FY 2024-25.

F. It is hereby affirmed that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.

G. Information required under Section 197 of the Companies Act, 2013, read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

1. List of top ten employees in terms of remuneration drawn in FY 2025-26:

Sr. No.	Name	Designation	Remuneration Received (CTC) (PA)	Qualification	Date of Appointment	Experience	Last Employment (If any)
1	Hetal Thakkar	CFO	-	B.B.A. & M.B.A.	01-03-2016	10	Nutec Infotech Pvt Ltd
2.	Tanvi Solanki	CS	1,44,000	CS & B.com	01-11-2023	5	-

2. Employees employed throughout the financial year, was in receipt of remuneration for that year which, in the aggregate, was not less than one crore and two lakh rupees:

There were no such employees who are in receipt of remuneration of one crore and two lakhs rupees and above throughout the financial year.

3. Employees employed for a part of the financial year, was in receipt of remuneration for any part of that year, at a rate which, in the aggregate, was not less than eight lakh and fifty thousand rupees per month:

There were no such employees who are in receipt of remuneration of eight lakh and fifty thousand rupees per month and above throughout the financial year.

4. Employees employed throughout the financial year or part thereof, was in receipt of remuneration in that year which, in the aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company:

There were no such employees employed throughout the financial year or part thereof who was in receipt of remuneration in that year which, in the aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company.

The Board of Directors of the Company affirmed that remuneration of all the Key Managerial Personnel of the Company is as per the Remuneration Policy of the Company.

5. Remuneration received by Managing Director from subsidiary company.

There are no subsidiary companies of Global Longlife Hospital and Research Limited. Hence, no remuneration has been received by the Managing Director.

For and on behalf of the Board of Directors

Date: May 30, 2026

Place: Ahmedabad

Dhruv Jani
Managing Director
DIN: 03154680

Sucheta Jani
Non-Executive Director
DIN: 06502321

Form No. AOC-2

(Pursuant to *clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014*)

Form for disclosure of particulars of contracts / arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm’s length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm’s length basis: **NIL**
2. Details of material contracts or arrangement or transactions at arm’s length basis: **NIL**
3. Details of contracts or arrangements or transactions not in the ordinary course of Business: **NIL**

For and on behalf of the Board of Directors

Date: May 30, 2026

Place: Ahmedabad

Dhruv Jani
Managing Director
DIN: 03154680

Sucheta Jani
Non-Executive Director
DIN: 06502321

Form No. MR-3
SECRETARIAL AUDIT REPORT

For The Financial Year Ended March 31, 2026
[Pursuant to section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Global Longlife Hospital and Research Limited
CIN: L85110GJ2012PLC068700
703, Sankalp Square, 3B, Beside Taj Skyline,
Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Global Longlife Hospital and Research Limited**. (hereinafter called the “company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on March 31, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by **Global Longlife Hospital and Research** (“the Company”) for the financial year ended on March 31, 2026 according to the provisions of:

- (i) The Companies Act, 2013 (“the Act”) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 (‘SCRA’) and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 (FEMA) and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (‘SEBI Act’):
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and circulars/ guidelines/Amendments issued there under;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and circulars/ guidelines/Amendments issued there under;

(c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 and circulars/ guidelines/Amendments issued there under;

(d) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and circulars/ guidelines/Amendments issued there under;

I have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with BSE Limited;

During the period under review the Company has complied with abovementioned provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. except following non-compliance:

As per Rule 4 of the Companies (Appointment and Qualification of Directors) Amendment Rules, 2014. The company was required to appoint Independent Director within three months of resignation of Mr. Sandeep Shah, But the said appointment was made after three months.

I have relied on the representation made by the Company and its Officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations as applicable to the Company.

I further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors, Independent Directors and Woman Director. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions of the Board and Committees were carried with requisite majority and captured in the Minutes.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Date: May 30, 2026
Place: Ahmedabad

For, Insiya Nalawala & Associates
Company Secretaries
Insiya Nalawala
Proprietor
M. No.: F13422
C P No.: 22786
Peer Review No.: 5443/2024
UDIN: F013422H000458702

Note: This Report is to be read with my letter of even date which is annexed as Annexure A forms an integral part of this report.

**To,
The Members,
Global Longlife Hospital and Research Limited
CIN: L85110GJ2012PLC068700
703, Sankalp Square, 3B, `Beside Taj Skyline,
Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India**

My report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of secretarial records. The verification was done on test basis, on the records and documents provided by the Management of the Company, to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices followed by me provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to verification of procedures on test basis.
5. Wherever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**Date: May 30, 2026
Place: Ahmedabad**

**For, Insiya Nalawala & Associates
Company Secretaries**

**Insiya Nalawala
Proprietor
M. No.: F13422
C P No.: 22786
Peer Review No.: 5443/2024
UDIN: F013422H000458702**

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW OF INDIAN ECONOMY

The Indian healthcare industry continues to witness significant growth driven by increasing healthcare awareness, rising disposable income, growing penetration of health insurance, government initiatives, technological advancements, and expansion of healthcare infrastructure. The sector includes hospitals, diagnostics, pharmaceuticals, medical devices, telemedicine, and allied healthcare services.

India's healthcare market is expected to grow steadily due to increasing demand for quality healthcare services, an ageing population, and rising prevalence of chronic diseases. Government initiatives such as Ayushman Bharat, digital healthcare missions, and increased public healthcare spending are expected to further strengthen the healthcare ecosystem.

The healthcare sector has also seen increased adoption of digital technologies, including teleconsultation, electronic medical records, AI-driven diagnostics, and data analytics, resulting in improved operational efficiencies and patient outcomes.

Global growth is projected at 3.3% in 2026, fully recovering from the April 2025 tariff-related downgrade and returning to its January 2025 level. Advanced economies (AEs) are expected to grow at 1.8%, driven largely by continued US resilience, while emerging market and developing economies (EMDEs) are projected to expand by 4.2%, slightly below initial expectations, reflecting lingering effects of tight financial conditions and trade uncertainty. Overall, growth stabilises but remains uneven and regionally divergent.

India's competitive advantage lies in its large pool of well-trained medical professionals. India is also cost-competitive compared to its peers in Asia and Western countries. The cost of surgery in India is about one-tenth of that in the US or Western Europe. The low cost of medical services has resulted in a rise in the country's medical tourism, attracting patients from across the world. Moreover, India has emerged as a hub for R&D activities for international players due to its relatively low cost of clinical research.

OUTLOOK

India's healthcare sector is extremely diversified and is full of opportunities in every segment, which includes providers, payers, and medical technology. India is a land full of opportunities for players in the medical devices industry. The country has also become one of the leading destinations for high-end diagnostic services with tremendous capital investment for advanced diagnostic facilities, thus catering to a greater proportion of the population. Besides, Indian medical service consumers have become more conscious towards their healthcare upkeep. Rising income levels, an ageing population, growing health awareness and a changing attitude towards preventive healthcare are expected to boost healthcare services demand in the future. Greater penetration of health insurance aided the rise in healthcare spending, a trend likely to intensify in the coming decade.

(Source: IBEF, CNBC, Economic Times)

1. INDUSTRY STRUCTURE AND DEVELOPMENT

Healthcare has become one of India's largest sectors, both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services, and increasing expenditure by public as well private players.

India's healthcare delivery system is categorised into two major components - public and private. The government, i.e., public healthcare system, comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of Primary Healthcare Centers (PHCs) in rural areas. The private sector provides majority of secondary, tertiary, and quaternary care institutions with major concentration in metros, tier-I, and tier-II cities.

India's competitive advantage lies in its large pool of well-trained medical professionals. India is also cost competitive compared to its peers in Asia and western countries. The cost of surgery in India is about one-tenth of that in the US or Western Europe. The low cost of medical services has resulted in a rise in the country's medical tourism, attracting patients from across the world. Moreover, India has emerged as a hub for R&D activities for international players due to its relatively low cost of clinical research.

Market Size

India continues to expand its healthcare infrastructure. In FY26, private hospitals are expected to add over 4,000 beds with investments of Rs. 11,500 crore (US\$ 1.34 billion). As of April 1, 2025, the country has 13,86,150 registered allopathic doctors and 7,51,768 AYUSH practitioners, resulting in a doctor-to-population ratio of 1:811. Medical education capacity is also growing, with 157 new medical colleges being established by upgrading district and referral hospitals, of which 131 are operational. Under the Central Sector Scheme for new AIIMS, 22 institutes have been approved, and undergraduate courses have commenced in 19. By April 2025, India had 74,306 postgraduate seats and 1,18,190 MBBS seats, strengthening the talent pipeline.

Investment activity in the sector remains strong. According to the Grant Thornton Bharat Pharma & Healthcare Dealtracker, Q1 2025 witnessed 71 deals worth Rs. 22,279 crore (US\$ 2.6 billion), with focus areas including speciality pharma, biotech, digital health, and CRAMS. The Drugs & Pharmaceuticals sector alone attracted FDI inflows of Rs. 2,10,940 crore (US\$ 24.62 billion) between April 2000 and June 2025. Hospitals and diagnostic centres received Rs. 1,04,970 crore (US\$ 12.25 billion), while medical and surgical appliances drew Rs. 33,933 crore (US\$ 3.96 billion).

Health insurance penetration is steadily rising. Total health insurance premiums stood at Rs. 1,18,688 crore (US\$ 13.84 billion) in FY25, up from Rs. 1,09,007 crore (US\$ 12.72 billion) in FY24. In July 2025, standalone health insurers' premiums rose 10.4% YoY to Rs. 3,622 crore (US\$ 422.7 million), reflecting growing adoption and demand for coverage.

Digital health and telemedicine are emerging as key growth drivers. The Indian digital health market, valued at Rs. 75,658 crore (US\$ 8.79 billion) in 2024, is projected to reach Rs. 4,11,275 crore (US\$ 47.80 billion) by 2033 at a CAGR of 17.67%. The telemedicine market is expected to reach Rs. 47,130 crore (US\$ 5.4 billion) by 2025, supported by demand for remote healthcare and advances in technology.

Medical tourism continues to strengthen India's global healthcare position. The market, valued at US\$ 7.69 billion in 2024, is expected to reach US\$ 14.31 billion by 2029. In 2023, around 634,561 foreign tourists visited India for medical treatment, accounting for 6.87% of total arrivals. With a medical value travel industry of US\$ 5-6 billion and over 500,000 international patients annually, India is among the leading global destinations for advanced treatment.

2. OPPORTUNITIES AND THREATS

The Indian medical devices sector has witnessed remarkable growth in recent years and is expected to reach Rs. 4,34,350 crore (US\$ 50 billion) by FY31 driven by increasing demand for quality healthcare, advancements in technology, and favorable government policies. Start-ups in this sector have been instrumental in fostering innovation, improving accessibility, and reducing costs.

Under GST 2.0, taxes on medical devices and consumables are reduced to 5% on most devices and supplies like diagnostic kits, reagents, glucometers, medical oxygen, gauze, bandages, surgical gloves, thermometers, down from 12-18% earlier.

(Source: IBEF)

3. SEGMENT-WISE / PRODUCT-WISE PERFORMANCE:

The company operates in the single segment i.e. Health Care and Hospital. The total revenue from operations is Nil in FY 2025-26 as compared to ₹ 57.73 lakhs in FY 2024-25. The Profit before interest and taxes is Nil in the FY 2025-26 as against profit of ₹ 37.54 lakhs for the FY 2024-2025.

4. OUTLOOK FOR FY 2026-2027

- We plan to expand our network into markets;
- We intend to maximize our operational efficiency by achieving greater integration and by implementing a stronger supply chain management.
- We have plan to alter name and object of the company.

5. RISK AND CONCERN

The Company's ability to foresee and manage business risks is crucial in achieving favourable results. Risk management at Global Longlife Hospital and Research Limited is an integral part of the business, focusing to mitigate the adverse impact of risks on business objectives. The Company has laid down a well-defined risk management procedure covering the risk identification, risk exposure, potential impact and risk mitigation process. The Board periodically reviews the risks and suggests steps to be taken to control and mitigate the same through a properly defined framework.

6. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has an adequate internal control system adopted for operating procedures, policies and process guidelines. The guidelines are well-documented with clearly defined authority limits corresponding with the level of responsibility for each functional area. Further, the Company has budgetary control system to monitor expenditure against approved budgets on an ongoing basis. The Company's robust internal audit programme which works to conduct a risk-based audit not only tests

the adherence to laid down policies and procedures but also suggests improvements in the current processes and systems.

7. DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

The Financial performance of the company during the FY 2025-26 as compared to FY 2024-2025 is as under:

Particulars	(Rs. In Lakhs)		
	2025-2026	2024-2025	% of Increase/Decrease
Gross Revenue from operations	0.00	57.73	-
Profit Before Tax	(98.80)	9.92	-
Profit after Tax	(171.95)	19.87	-

Operational Performance

The Company continued to focus on improving operational efficiency leading to better returns for the shareholders. Further, the company has significantly enhanced its operational performance by establishing prudent risk management framework.

8. MATERIAL DEVELOPMENT IN HUMAN RESOURCES/INDUSTRIAL RELATIONSHIP FRONT, INCLUDING NUMBER OF PEPOLE EMPLOYED

Human resource practices and policies at Global Longlife Hospital and Research Limited ensure that all employees, wherever they work, whatever their role is, are always treated equally, fairly and respectfully. We maintain consistent and transparent diversity policies.

Our human resource team believes in personnel management, which involves planning, organising, directing and controlling of the recruitment and resource management, training & development, compensation, integration and maintenance of people for the purpose of contributing to organizational, individual and social goals.

People power is one of the pillars of success of company. As on 31st March, 2026 the Company employs 03 employees. Going ahead, the Company aims to retain and develop the existing employees and align their goals with the common business vision and mission.

9. THE DETAILS OF SIGNIFICANT CHANGES IN KEY FINANCIAL RATIOS

During the financial year, the details of significant change in the key financial ratios i.e. change of more than 25% as compared to the previous year along with the detailed explanation is summarized below on standalone basis:

Sr. No.	Key Financial Ratios	F.Y. 2025-26	F.Y. 2024-25	Changes in %	Reasons for change
1.	Debtors Turnover Ratio	0.00	0.51	100%	Nil sales during the year led to minimal receivables, causing a substantial fluctuation

					in the ratio.
2.	Inventory Turnover Ratio	0.00	2.64	100%	Absence of operations and no opening or closing inventory during the year resulted in a significant variance in the ratio.
3.	Interest Coverage Ratio (in times)	0.00	1.36	100%	Lack of revenue & nil interest exps leading major variance in the ratio
4.	Current Ratio	1691.15	405.24	317.32%	The current ratio decreased mainly due to a significant reduction in cash and cash equivalents, despite an increase in other current assets. Changes in the composition of current liabilities also contributed to the overall decline in liquidity.
5.	Debt Equity Ratio (in times)	0.00	0.053	76%	Due to reduce liability leading major variance in the ratio.
6.	Operating Margin (in %)	0.00	-216.39	100%	Lack of Operating Income, leading to a major variance in the ratio.
7.	Net Profit Margin (in %)	0.00	3.55	100%	Lack of revenue coupled with fixed expenses resulted in abnormal/negative profitability, leading to a major variance in the ratio.

10. The Return on Net Worth during the FY 2025-26 was -7.24 % as compared to 0.74 % in FY 2024-25. The changes in the return on Net Worth is mainly due to negative profit in the FY 2025-26.

11. CAUTIONARY STATEMENT

Statement made in the Management Discussion and Analysis describing the various parts may be “forward looking statement” within the meaning of application securities laws and regulations. The actual result may differ from those expectations depending upon the economic conditions, changes in Government regulation and amendments in tax laws and other internal and external factors.

FINANCIAL STATEMENTS OF FY 2025-2026

- ❖ **Audit Report**
- ❖ **Balance Sheet**
- ❖ **Statement of Profit and Loss Account**
- ❖ **Cash Flow**
- ❖ **Notes to Accounts**



ANNUAL AUDIT REPORT

FOR

FINANCIAL YEAR
2025-2026

OF

**Global Longlife Hospital and
Research Limited**

Auditor
M/s. R.B. Gohil & Co.
Chartered Accountants
1st Floor, K.P. Shah House - 1,
K.V. Road, Jamnagar - 361001



INDEPENDENT AUDITOR'S REPORT

To the Members of
GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

I. Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED** Company ("the Company"), which comprise the balance sheet as at 31st March, 2026, the statement of profit and loss for the year end and the statement of cash flows for the year ended on that date, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026 and its profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have nothing to communicate in this regard.





R. B. Gohil & Co.

Chartered Accountants

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report, but does not include the Financial Statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

1. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit





R. B. Gohil & Co.

Chartered Accountants

- evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
2. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
 3. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
 4. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.





R. B. Gohil & Co.

Chartered Accountants

II .Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), as amended, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to extent applicable.
2. As required by section 143 (3) of the Act, we report that:
 - a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b. in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act

- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.





R. B. Gohil & Co.

Chartered Accountants

- IV. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- iv. No dividend declared or paid during the year by the Company. So reporting under this clause is not required.
- v. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has no feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software.

For, M/s. RB Gohil & Co.
Chartered Accountants
FRN No. 119360W



R. B. Gohil
CA Raghubha B. Gohil
Partner
M.No.104997

UDIN: 26104997KGILKR5984

Place: Jamnagar
Date: 07/05/2026



R. B. Gohil & Co.

Chartered Accountants

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under ‘Report on Other Legal & Regulatory Requirement’ section of our report to the members of GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED of even date:

In terms of the information and explanations sought by us and given by the company and the books and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- i. The Company does not have any Property, Plant and Equipment (including Right-of-Use assets) or intangible assets during the year. Accordingly, the provisions of clause (i) of the Companies (Auditor’s Report) Order, 2020 are not applicable to the Company.
- ii. (a) The Company does not have any inventory during the year. Accordingly, the provisions of clause (ii) of the Companies (Auditor’s Report) Order, 2020 are not applicable to the Company.
(b) As explained to us, the Company has not sanctioned with the working capital limits in excess of five crore rupees, in aggregate from banks or financial institution on the basis of security of Immovable assets, hence reporting under this clause is not required.
- iii. The Company has not made any investments in, provided any guarantee or security, or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year. Accordingly, the provisions of clause (iii) of the Companies (Auditor’s Report) Order, 2020 are not applicable to the Company.
- iv. The Company has not granted any loans or made any investments or provided any guarantees or securities to the parties covered under section 185 and 186 of the Companies Act, 2013. Therefore, the provisions of Clause 3(iv) of the said Order are not applicable to the Company.
- v. In our opinion and according to the information and explanations given to us, the company has not accepted any deposits and accordingly paragraph 3 (v) of the order is not applicable.
- vi. In our opinion and according to the information and explanations given to us, maintenance of cost records has been specified by the Central Government under sub-section (1) of section 148 of Companies Act is not applicable, hence reporting under this clause is not required.
- vii. (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, GST, Cess and any other statutory dues with the appropriate authorities.





R. B. Gohil & Co.

Chartered Accountants

According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at reporting date for a period of more than six months from the date on when they become payable.

- (b) According to the information and explanation given to us and the records of the company examined by us, there are no dues of income tax, sales tax, service tax, GST, duty of customs, duty of excise, value added tax outstanding on account of any dispute.
- viii. According to the information and explanation given to us and the records of the company examined by us, there are no any transactions which are not recorded in the books of accounts and disclosed or surrendered as income during the year in the tax assessment under the Income Tax Act, 1961. Accordingly paragraph 3 (viii) of the order is not applicable.
- ix. (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender. Accordingly, reporting under this clause is not required.
- (b) According to the information and explanation given to us, the company has not been declared as a wilful defaulter by any bank or financial institution or other lender;
- (c) According to the information and explanations given to us, the Company has not obtained any term loans during the year. Accordingly, reporting on utilization of term loans does not arise.
- (d) "According to the information and explanations given to us, the Company has not raised any short-term funds during the year. Accordingly, reporting on utilization for long-term purposes does not arise.
- (e) According to the information and explanation given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
- (f) According to the information and explanation given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.
- x. (a) During the year, the Company has not raised any funds through Initial Public offer or Further Public Offer (Including debt instruments). Accordingly, reporting under clause X(a) of paragraph 3 of the Oder does not arise.





R. B. Gohil & Co.

Chartered Accountants

- (b) According to the information and explanations given to us and based on our examination of the records of the company, the company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Accordingly, reporting under this clause is not required.
- xi. (a) Based upon the audit procedures performed and according to the information and explanations given to us, no fraud by the company or any fraud on the company has been noticed or reported during the year.
- (b) Based upon the audit procedures performed and according to the information and explanations given to us, as no fraud has been noticed during the year, there is no requirement to file report under section 143 (12) of The Companies Act in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) Based upon the audit procedures performed and according to the information and explanations given to us, No whistle-blower complaints has been received by the company during the year.
- xii. In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.
- xiii. According to the information and explanations given to us and based on our examination of the records of the company, transactions with the related parties are in compliance with section 177 and 188 of the Act. Where applicable, the details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. (a) In our opinion the company has an adequate internal audit system commensurate with the size and the nature of its business.
- (b) We have considered the internal audit reports issued to the company during the year and covering the period up to 31st March, 2026 for the period under audit.
- xv. According to the information and explanations given to us and based on our examination of the records of the company, the company has not entered into non-cash transactions with directors or persons connected with them. Accordingly, paragraph 3(xv) of the order is not applicable.
- xvi. (a) According to the information and explanations given to us and based on our examination of the records of the company, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.
- (b) According to the information and explanations given to us and based on our examination of the records of the company, the company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the reserve Bank of India Act, 1934.





R. B. Gohil & Co.

Chartered Accountants

- (c) In our opinion, the Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India.
- (d) In our opinion, the Company is not a Core Investment Company (CIC) hence reporting under this clause is not required.
- xvii. According to the information and explanations given to us and based on our examination of the records of the company, the Company has not incurred cash losses in the financial year and in the immediately preceding financial year.
- xviii. According to the information and explanations given to us and based on our examination of the records of the company, there is no resignation of Statutory Auditors during the year, hence reporting under this clause is not applicable.
- xix. No material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of 1 year from the balance sheet date.
- xx. In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For, M/s. RB Gohil & Co.
Chartered Accountants
FRN No. 119360W



R. B. Gohil
CA Raghubha B. Gohil
Partner
M.No.104997

UDIN: 26104997KGILKR5984

Place: Jamnagar
Date: 07/05/2026



Annexure B” to the Independent Auditor’s Report

(Referred to in paragraph 2 (f) under ‘Report on other legal and regulatory requirements’ section of our report to the Members of **GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED** of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED** (“the Company”) as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.





R. B. Gohil & Co.

Chartered Accountants

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the AS financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For, M/s. RB Gohil & Co.

Chartered Accountants

FRN No. 119360W



CA Raghubha B. Gohil

Partner

M.No. 104997

UDIN: 26104997KGILKR5984

Place: Jamnagar

Date: 07/05/2026

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

(CIN: L85110GJ2012PLC068700)

Balance Sheet as at 31-March-2026

(Rs in lakhs)

Particulars	Note	31-March-2026	31-March-2025
I. EQUITY AND LIABILITIES			
(1) Shareholders' funds			
(a) Share Capital	3	1,050.00	1,050.00
(b) Reserves and Surplus	4	1,324.93	1,628.88
(C) Money received against share warrants		-	-
Total		2,374.93	2,678.88
(2) Share application money pending to allotment			
		-	-
(3) Non-current liabilities			
(a) Long-term borrowings		-	-
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long-term liabilities		-	-
(d) Long-term provisions		-	-
Total		-	-
(4) Current liabilities			
(a) Short-term borrowings		-	-
(b) Trade payables		-	-
- Due to Micro and small enterprises		-	-
- Due to others		-	-
(C) Other Current Liabilities	5	-	1.20
(d) Short-term Provisions	6	1.20	4.38
Total		1.20	5.58
Total Equity and Liabilities		2,376.13	2,684.46
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment			
(i) Tangible assets		-	-
(ii) Intangible assets		-	-
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current Investments	7	-	3.00
(c) Deferred Tax Assets (net)	8	234.78	234.78
(d) Long-term loans and advances		-	-
(e) Other Non-current Assets	9	111.97	182.95
Total		346.75	420.73
(2) Current assets			
(a) Current investments		-	-
(b) Inventories		-	-
(c) Trade receivables	10	22.88	32.12
(d) Cash and cash equivalents	11	1,701.70	2,149.18
(e) Short-term loans and advances	12	0.95	26.36
(f) Other current assets	13	303.85	2,283.73
Total		2,029.38	2,283.73
Total Assets		2,376.13	2,684.46



See accompanying notes to the financial statements

As per our report of even date
For, M/s. R B GOHIL & Co.
Chartered Accountants
Firm's Registration No. 119360W


CA Raghubha B. Gohil
Partner
Membership No. 104997
UDIN: 26104997KGILKR5984
Place: Jamnagar
Date: 07-05-2026



For and on behalf of the Board of
GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Dhruv S Jani
Managi
DIN - 03154680

Sucheta D Jani
Director
DIN - 065022321

Hetal Thakkar
Director and CFO
DIN - 10756299

Tanvi Solanki
Company Secretary
A58435

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED
(CIN: L85110GJ2012PLC068700)
Statement of Profit and loss for the year ended 31-March-2026

(Rs in lakhs)

Particulars	Note	31-March-2026	31-March-2025
Revenue from Operations	14	-	57.73
Other Income	15	0.52	501.61
Total Income		0.52	559.34
Expenses			
Cost of materials consumed		-	-
Purchases of Stock-in-Trade		-	-
Change in Inventories of work in progress and finished goods	17	-	43.72
Stock-in-Trade		-	-
Direct Exp.	16	-	182.65
Employee Benefit Expenses	18	19.44	113.58
Finance Costs	19	0.03	27.62
Depreciation and Amortization Expenses	20	-	48.19
Other Expenses	21	79.85	133.66
Total expenses		99.32	549.42
Profit/(Loss) before Exceptional and Extraordinary Item and Tax			
Exceptional Item		-98.80	9.92
Profit/(Loss) before Extraordinary Item and Tax			
Extraordinary Item		-98.80	9.92
Profit/(Loss) before Tax			
Tax Expenses	22	-98.80	9.92
- Current Tax		-	2.58
- Deferred Tax		-	-12.53
- Excess/Short Provision Written back/off		73.15	-
Profit/(Loss) after Tax		-171.95	19.87
Earnings Per Share (Face Value per Share Rs.10 each)			
-Basic (In Rs)	23	-1.64	0.19
-Diluted (In Rs)	23	-1.64	0.19

See accompanying notes to the financial statements

As per our report of even date
For, M/s. R B GOHIL & Co.
Chartered Accountants
Firm's Registration No. 119360W

CA Raghubha B. Gohil
Partner
Membership No. 104997
UDIN: 26104997KGILKR5984
Place: Jamnagar
Date: 07-05-2026



For and on behalf of the Board of
GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Dhruv S Jani
Managing Director
DIN - 03154680

Sucheta D Jani
Director
DIN - 065022321

Hetal Thakkar
Director and CFO
DIN - 10756299

Tanvi Solanki
Company Secretary
A58435

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED
(CIN: L85110GJ2012PLC068700)

Cash Flow Statement for the year ended 31-March-2026

Particulars	Note	(Rs in lakhs)	
		31-March-2026	31-March-2025
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		-98.80	9.92
Depreciation and Amortisation Expense		-	48.19
Loss/(Gain) on Sale / Discard of Assets (Net)		-	-431.18
Change in reserve & surplus		-	65.86
Net Loss/(gain) on sale of investment		-132.00	-
Bank charges		-	-57.12
Non Cash Expenses		0.03	-
Dividend Income		70.76	67.79
Interest Income		-0.45	-0.45
Finance Costs		-0.07	-12.59
Operating Profit before working capital changes		-	27.62
		-160.53	-281.96
Adjustment for:			
Inventories		-	43.72
Trade Receivables		-	162.48
Other Current Assets		9.24	-
Trade Payables		-247.56	1,637.42
Other Current Liabilities		-	-255.88
Short-term Provisions		-1.20	-42.39
		-0.60	-4.94
Cash (Used in)/Generated from Operations		-	-
Tax paid(Net)		-400.65	1,258.45
Net Cash (Used in)/Generated from Operating Activities		50.32	26.38
		-450.97	1,232.07
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Property, Plant and Equipment		-	-7.24
Sale of Property, Plant and Equipment		-	2,117.23
Proceeds from sale of Equity Instruments		-	-
Purchase of Mutual Funds		3.00	-
Proceeds from Sale/Redemption of Mutual Funds		-	-1,850.00
Investment in Term Deposits		-	1,907.12
Interest received		-	-0.28
Dividend received		0.07	12.59
Net Cash (Used in)/Generated from Investing Activities		0.45	0.45
		3.52	2,179.88
CASH FLOW FROM FINANCING ACTIVITIES			
Repayment of Long Term Borrowings		-	-340.97
Repayment of Short Term Borrowings		-	-932.71
Bank charges paid		-	-
Interest Paid		-0.03	-
Net Cash (Used in)/Generated from Financing Activities		-	-27.62
		-0.03	-1,301.30
Net Increase/(Decrease) in Cash and Cash Equivalents		-447.48	2,110.64
Opening Balance of Cash and Cash Equivalents		2,149.18	38.54
Exchange difference of Foreign Currency Cash and Cash equivalents		-	-
Closing Balance of Cash and Cash Equivalents		-	-
	13	1,701.70	2,149.18

Components of cash and cash equivalents	31-March-2026	31-March-2025
Cash on hand	0.06	0.06
Cheques, drafts on hand	-	-
Balances with banks in current accounts	-	-
Bank Deposit having maturity of less than 3 months	1,701.64	2,149.13
Others	-	-
Cash and cash equivalents as per Cash Flow Statement	-	-
Note:	1,701.70	2,149.19

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

See accompanying notes to the financial statements

As per our report of even date
For, M/s. R B GOHIL & Co.
Chartered Accountants
Firm's Registration No. 119360W

CA Raghubha B. Gohil
Partner
Membership No. 104997
UDIN: 26104997KGILKR5984
Place: Jamnagar
Date: 07-05-2026



For and on behalf of the Board of
GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Dhruv S Jani
Managing Director
DIN - 03154680

Sucheta D Jani
Director
DIN - 065022321

Hetal Thakkar
Director and CFO
DIN - 10756299

Tanvi Solanki
Company Secretary
A58435

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED
(CIN: L85110GJ2012PLCD68700)
Notes forming part of the Financial Statements

3 Share Capital

(Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Authorised Share Capital		
Equity Shares, of Rs. 10 each, 10500000 (Previous Year -10500000) Equity Shares	1,050.00	1,050.00
Issued, Subscribed and Fully Paid up Share Capital		
Equity Shares, of Rs. 10 each, 10500000 (Previous Year -10500000) Equity Shares paid up	1,050.00	1,050.00
Total	1,050.00	1,050.00

(i) Reconciliation of number of shares

Particulars	31-March-2026		31-March-2025	
	No. of shares	(Rs in lakhs)	No. of shares	(Rs in lakhs)
Equity Shares				
Opening Balance	1,05,00,000	1,050.00	1,05,00,000	1,050.00
Issued during the year (IPO)	-	-	-	-
Deletion	-	-	-	-
Closing balance	1,05,00,000	1,050.00	1,05,00,000	1,050.00

(ii) Rights, preferences and restrictions attached to shares

Equity Shares: The Company has one class of equity shares. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

(iii) Details of Shares held by shareholders holding more than 5% of the aggregate shares in the company

Equity Shares	31-March-2026		31-March-2025		
	Name of Shareholder	No. of shares	In %	No. of shares	In %
	Dhruv Jani	24,00,990	22.87%	38,98,990	37.13%
	Sucheta Jani	-	0.00%	18,00,000	17.14%

(iv) Shares held by Promoters at the end of the year 31-March-2026

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Dhruv Jani	equity	24,00,990	22.87%	-14.26%
Sucheta Jani	equity	-	0.00%	-17.14%
Aruna Jani	equity	1,000	0.01%	0.00%

Shares held by Promoters at the end of the year 31-March-2025

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Sureshkumar Jani	equity	-	0.00%	-14.29%
Dhruv Jani	equity	38,98,990	37.13%	14.29%
Sucheta Jani	equity	18,00,000	17.14%	0.00%
Aruna Jani	equity	1,000	0.01%	0.00%



(Rs in lakhs)		
4 Reserves and Surplus	31-March-2026	31-March-2025
Particulars		
Securities Premium		
Opening Balance	1,761.95	1,761.95
Less: Deletion	132.00	-
Closing Balance	1,629.95	1,761.95
General Reserve		
Opening Balance	65.86	65.86
Closing Balance	65.86	65.86
Statement of Profit and loss		
Balance at the beginning of the year	-198.94	-218.81
Add: Profit/(loss) during the year	-171.95	19.87
Balance at the end of the year	-370.89	-198.94
Total	1,324.93	1,628.88

(Rs in lakhs)		
5 Other current liabilities	31-March-2026	31-March-2025
Particulars		
TDS Payable	-	1.20
Total	-	1.20

(Rs in lakhs)		
6 Short term provisions	31-March-2026	31-March-2025
Particulars		
Provision for employee benefits	0.12	-
Others		
-Provision for Audit Fees	1.08	1.80
-Provision for Tax	-	2.58
Total	1.20	4.38



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

(CIN: L85110GJ2012PLC068700)

Notes forming part of the Financial Statements

7 Non current investments (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Unquoted Trade Investments in Equity Instruments -Kalupur Bank Share	-	3.00
Total	-	3.00

7.1 Details of Investments (Rs in lakhs)

Name of Entity	No of Shares	31-March-2026	No of Shares	31-March-2025
Investments in Other companies' Equity Instruments (Unquoted) The Kalupur Commercial Co.op. Bank Ltd. [equity shares of Rs.25 Face value each]	-	-	12,000	3.00

8 Deferred tax assets net (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Deffered Tax Assets (Net)	234.78	234.78
Total	234.78	234.78

9 Other non current assets (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Security Deposits	0.90	0.90
Others -Preliminary Expenses	111.07	182.05
Total	111.97	182.95

10 Trade receivables (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Unsecured considered good	22.88	32.12
Total	22.88	32.12

10.1 Trade Receivables ageing schedule as at 31-March-2026 (Rs in lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables-considered good	-	-	22.88	-	-	22.88
Undisputed Trade Receivables-considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables considered good	-	-	-	-	-	-
Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
Sub total	-	-	22.88	-	-	22.88
Undue - considered good	-	-	-	-	-	-
Total	-	-	22.88	-	-	22.88

10.2 Trade Receivables ageing schedule as at 31-March-2025 (Rs in lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables-considered good	-	25.97	6.14	-	-	32.12
Undisputed Trade Receivables-considered doubtful	-	-	-	-	-	-
Disputed Trade Receivables considered good	-	-	-	-	-	-
Disputed Trade Receivables-considered doubtful	-	-	-	-	-	-
Sub total	-	25.97	6.14	-	-	32.12
Undue - considered good	-	-	-	-	-	-
Total	-	25.97	6.14	-	-	32.12



11 Cash and cash equivalents (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Cash on hand	0.06	0.06
Balances with banks in current accounts	1,701.64	2,149.12
Total	1,701.70	2,149.18

12 Short term loans and advances (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Balances with Government Authorities -TDS Receivable	0.95	26.36
Total	0.95	26.36

13 Other current assets (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
F D with Kalapur Bank	-	4.31
Other Receivables	301.10	46.94
Prepaid Expense	2.75	4.82
Total	303.85	56.07

14 Revenue from operations (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Sale of services	-	57.73
Total	-	57.73

15 Other Income (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Interest Income		
-Interest of Bank FD	0.07	8.30
-Interest of IT Refund	-	4.07
-Others	-	0.22
Dividend Income	0.45	0.45
Income from Sale of Fixed Asset	-	431.18
Income from Sale of Mutual Fund	-	57.12
Other Income	-	0.27
Total	0.52	501.61

16 Direct Exp. (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Ambulance Expense	-	0.06
Bio Medical Waste Collection Expense	-	0.01
Cathlab Expense	-	0.89
CMC Expense	-	0.02
Consultant Expense	-	110.86
Implant Expense	-	2.47
OPD Discount	-	2.25
P M JAY - Discount	-	64.40
Pathology Expense	-	1.68
Patients/Staff Food Expense	-	0.01
Total	-	182.65

17 Change in Inventories of work in progress and finished goods (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Opening Inventories		
Finished Goods	-	43.72
Less: Closing Inventories		
Finished Goods	-	-
Total	-	43.72



18 Employee benefit expenses (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Salaries and wages		
-Director's Remuneration	18.00	57.00
-Salaries and Wages	1.44	56.41
Contribution to provident and other funds		
-Employers Contribution to PF	-	0.14
Staff welfare expenses	-	0.03
Total	19.44	113.58

19 Finance costs (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Interest expense	-	27.30
Other borrowing costs		
-Bank Charges	0.03	0.32
Total	0.03	27.62

20 Depreciation and amortization expenses (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Depreciation and Amortization	-	48.19
Total	-	48.19

21 Other expenses (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Auditors' Remuneration	1.18	3.18
Administrative expenses	-	0.81
Advertisement	0.26	-
Conveyance expenses	-	0.13
Insurance	-	0.19
Rent	2.06	3.65
Repairs to buildings	-	2.54
Rates and taxes	0.13	0.13
Telephone expenses	-	0.83
Travelling Expenses	-	1.44
AMC Expense	-	1.98
Computer Expense	-	0.04
Courier Expense	-	0.01
Diwali gift Expense	-	0.45
Donation	-	0.50
Electricity Expense	0.06	3.06
Electricity Transmission Charges	-	1.50
Interest of Statutory Dues	-	1.92
Internet Expense	0.16	0.46
IT Inhouse Expense	0.27	1.54
Medicines Disposable Expense	-	0.02
Office Expense	0.17	0.64
Petrol Expense	-	0.16
PF Admin Charges	-	0.02
Preliminary Expenses Written Off	70.76	67.79
Professional Expense	4.80	11.07
ROC Fees Expense	-	0.11
Rounding Off	-	2.01
Solar Project Land Rent Expenses	-	0.53
Stationary Expense	-	0.04
Temple Expense	-	0.22
TPA Discount	-	26.69
Total	79.85	133.66

22 Tax Expenses (Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Current Tax	-	2.58
Deferred Tax	-	-12.53
Excess/Short Provision Written back/off	73.15	-
Total	73.15	-9.95



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

(CIN: L85110GJ2012PLC068700)

Notes forming part of the Financial Statements

23 Earning per share

Particulars	31-March-2026	31-March-2025
Profit attributable to equity shareholders (Rs in lakhs)	-171.95	19.87
Weighted average number of Equity Shares	1,05,00,000	1,05,00,000
Earnings per share basic (Rs)	-1.64	0.19
Earnings per share diluted (Rs)	-1.64	0.19
Face value per equity share (Rs)	10	10

24 Auditors' Remuneration

(Rs in lakhs)

Particulars	31-March-2026	31-March-2025
Payments to auditor as - Auditor	1.18	3.18
Total	1.18	3.18

25 Related Party Disclosure

(i) List of Related Parties

Relationship

Dhruv Jani	Director
Sureshkumar Jani	Director (Resigned with effect from 03/10/2024)
Sucheta Jani	Director
Aruna Jani	Relative of Director
Hetal Thakkar	CFO & Director (Appointed from 30/08/2024)
Dhruv Cotfab Pvt Ltd	Company in which Director is Shareholder
Tanvi Solanki	Company secretary

(ii) Related Party Transactions

(Rs in lakhs)

Particulars	Relationship	31-March-2026	31-March-2025
Directors Remuneration			
- Dhruv Jani	Director	12.00	36.00
- Sureshkumar Jani	Director	-	15.00
- Sucheta Jani	Director	6.00	12.00
Loan Repaid by the company			
- Dhruv Jani	Director	2,174.17	996.28
- Sureshkumar Jani	Director	-	20.00
Salary			
- Hetal Thakkar	CFO & Director	-	6.10
- Tanvi Solanki	Company secretary	1.44	-
Loan taken by the company			
- Dhruv Jani	Director	2,174.17	996.28
- Sureshkumar Jani	Director	-	20.00



26 Ratio Analysis

Particulars	Numerator/Denominator	31-March-2026	31-March-2025	Change in %
(a) Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	1,691.15	405.24	317.32%
(b) Return on Equity Ratio	$\frac{\text{Profit after Tax}}{\text{Average Shareholder's Equity}}$	-6.80%	0.75%	-1002.65%
(c) Inventory turnover ratio	$\frac{\text{Total Turnover}}{\text{Average Inventories}}$	-	2.64	-100.00%
(d) Trade receivables turnover ratio	$\frac{\text{Total Turnover}}{\text{Average Trade Receivable}}$	-	0.51	-100.00%
(e) Net capital turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Working Capital}}$	-	0.03	-100.00%
(f) Net profit ratio	$\frac{\text{Net Profit}}{\text{Total Turnover}}$	0.00%	34.42%	-100.00%
(g) Return on Capital employed	$\frac{\text{Earning before Interest and taxes}}{\text{Capital Employed}}$	-4.16%	1.40%	-396.72%

Reasons for Variances

- (a) Current Ratio - The current ratio decreased mainly due to a significant reduction in cash and cash equivalents, despite an increase in other current assets. Changes in the composition of current liabilities also contributed to the overall decline in liquidity.
- (b) Return on Equity Ratio - Nil sales during the year led to loss in current year, causing a substantial fluctuation in the ratio.
- (c) Inventory turnover ratio - Absence of operations and no opening or closing inventory during the year resulted in a significant variance in the ratio.
- (d) Trade Receivable turnover ratio - Nil sales during the year led to minimal receivables, causing a substantial fluctuation in the ratio.
- (e) Net capital turnover ratio - Zero turnover in the current year has led to a significant variation, as the ratio does not reflect normal business activity.
- (f) Net profit ratio - Lack of revenue coupled with fixed expenses resulted in abnormal/negative profitability, leading to a major variance in the ratio.
- (g) Return on Capital employed - Nil sales during the year led to loss in current year, causing a substantial fluctuation in the ratio.

27 Additional Regulatory Information (as per the Schedule III requirements)

- Title deeds of Immovable Properties not held in name of the Company
As of the last date of the current and previous financial year, the company did not hold any assets.
- Compliance with approved Scheme(s) of Arrangements
There is no Scheme of Arrangements approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.
- Wilful Defaulter
The company is not declared as wilful defaulter by any bank or financial Institution or other lender.
- Relationship with Struck off Companies
The company does not have any transactions with struck off companies.
- Loans or Advances in the nature of loans granted to promoters, directors, KMPs and the related parties
There is no Loans or advances granted to the Promoters, directors, KMP and the relative of their during the period ended March 2026, and March 2025.
- Details of Benami Property held
As of the last date of the current and previous financial year, the company did not hold any assets.
- Registration of charges with Registrar of Companies
Company has register all it's charges within time or extended time period given in the companies act, 2013.

28 Regrouping

These financial statements have been prepared in the format prescribed by the Revised Schedule III to the Companies Act 2013. Previous year figures have been regrouped / re-classified to confirm to the classification of the current period.

As per our report of even date
For, M/s. R B GOHIL & Co.
Chartered Accountants
Firm's Registration No. 119360W



CA Raghubha B. Gohil
Partner
Membership No. 104997
UDIN: 26104997KGILKR5984
Place: Jamnagar
Date: 07-05-2026

Dhruv S Jani
Managing
DIN - 03154680

For and on behalf of the Board of
GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Sucheta D Jani Hetal Thakkar
Director Director and CFO
DIN - 065022321 DIN - 10756299

Place: Ahmedabad
Date: 07-05-2026

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

(CIN: L85110GJ2012PLC068700)

Notes forming part of the Financial Statements

1. COMPANY INFORMATION

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED ("The Company" converted in to Limited from Private Limited in the month of August 2021) is a limited company limited by shares which was incorporated in the year 2012 under the provision of Companies Act, 1956. The company is Multispecialty Hospital providing Medical & Allied Services. The company was established on the basis of innovative idea of Director Mr. Suresh Babulal Jani. On 04th May, 2022 the equity shares of the Company have been listed on the SME Platform of Bombay Stock Exchange Limited. The financial statements of the Company for the year ended 31st March, 2023 were approved and adopted by board of directors in their meeting held on 30th May 2023.

2. SIGNIFICANT ACCOUNTING POLICIES

a. Basis of Preparation

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India ('Indian GAAP') to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013, as applicable. The financial statements have been prepared under the historical cost convention on accrual basis, except for certain financial instruments which are measured at fair value.

b. Use of Estimates

The preparation of financial statements requires the management of the Company to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to the contingent liabilities as at the date of the financial statements and reported amounts of income and expense during the year. Examples of such estimates include provisions for doubtful receivables, provision for income taxes, the useful lives of depreciable Property, Plant and Equipment and provision for impairment. Future results could differ due to changes in these estimates and the difference between the actual result and the estimates are recognised in the period in which the results are known / materialise.

c. Property, Plant and Equipment

Property, Plant and Equipment are stated at cost, less accumulated depreciation / amortisation. Costs include all expenses incurred to bring the asset to its present location and condition.

d. Depreciation and amortization

In respect of Property, Plant and Equipment (other than freehold land and capital work-in-progress) acquired during the year, depreciation/amortisation is charged on a straight line basis so as to write-off the cost of the assets over the useful lives.

As of the last date of the financial year, the company did not hold any assets.

Type of Assets	Useful Life
Buildings	30 Years
Plant and Equipment	15 Years
Medical Equipment & Plant	13 Years
Furniture and Fixtures	10 Years
Electrical equipment	5 Years
Computers	3 Years
Software	3 Years

e. Impairment of assets

At each balance sheet date, the management reviews the carrying amounts of its assets included in each cash generating unit to determine whether there is any indication that those assets were impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of impairment. Recoverable amount is the higher of an asset's net selling price and value in use. In assessing value in use, the estimated future cash flows expected from the continuing use of the asset and from its disposal are discounted to their present value using a pre-tax discount rate that reflects the current market assessments of time value of money and the risks specific to the asset. Reversal of impairment loss is recognised as income in the statement of profit and loss.

f. Investment

Long-term investments and current maturities of long-term investments are stated at cost, less provision for other than temporary diminution in value. Current investments, except for current maturities of long-term investments, comprising investments in mutual funds, government securities and bonds are stated at the lower of cost and fair value.

g. Inventories

Raw materials are carried at the lower of cost and net realisable value. Cost is determined on a weighted average basis. Purchased goods-in-transit are carried at cost. Work-in-progress is carried at the lower of cost and net realisable value. Stores and spare parts are carried at lower of cost and net realisable value. Finished goods produced or purchased by the Company are carried at lower of cost and net realisable value. Cost includes direct material and labour cost and a proportion of manufacturing overheads.



The valuation for inventories is as follows;

Classification	Valuation Policy
Finished Goods	At lower of cost or net realizable value.
Raw Material	At lower of cost or net realizable value.
WIP	At Cost
Consumables	At Cost

h Cash and cash equivalents

The Company considers all highly liquid financial instruments, which are readily convertible into known amount of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents.

i Revenue recognition

Revenue from the sale of goods are recognised upon delivery, which is when title passes to the customer. Revenue is reported net of discounts.

Dividend is recorded when the right to receive payment is established. Interest income is recognised on time proportion basis taking into account the amount outstanding and the rate applicable.

j Employee Benefits

Post-employment benefit plans

Contributions to defined contribution retirement benefit schemes are recognised as expense when employees have rendered services entitling them to such benefits.

For defined benefit schemes, the cost of providing benefits is determined using the Projected Unit Credit Method, with actuarial valuations being carried out at each balance sheet date. Actuarial gains and losses are recognised in full in the statement of profit and loss for the period in which they occur. Past service cost is recognised immediately to the extent that the benefits are already vested, or amortised on a straight-line basis over the average period until the benefits become vested.

The retirement benefit obligation recognised in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognised past service cost, and as reduced by the fair value of scheme assets. Any asset resulting from this calculation is limited to the present value of available refunds and reductions in future contributions to the scheme.

Other employee benefits

The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees is recognised during the period when the employee renders the service. These benefits include compensated absences such as paid annual leave, overseas social security contributions and performance incentives.

Compensated absences which are not expected to occur within twelve months after the end of the period in which the employee renders the related services are recognised as an actuarially determined liability at the present value of the defined benefit obligation at the balance sheet date.

k Foreign currency transactions

Income and expense in foreign currencies are converted at exchange rates prevailing on the date of the transaction. Foreign currency monetary assets and liabilities other than net investments in non-integral foreign operations are translated at the exchange rate prevailing on the balance sheet date and exchange gains and losses are recognised in the statement of profit and loss. Exchange difference arising on a monetary item that, in substance, forms part of an enterprise's net investments in a non-integral foreign operation are accumulated in a foreign currency translation reserve.

l Taxation

Current income tax expense comprises taxes on income from operations in India and in foreign jurisdictions. Income tax payable in India is determined in accordance with the provisions of the Income Tax Act, 1961. Tax expense relating to foreign operations is determined in accordance with tax laws applicable in countries where such operations are domiciled.

Minimum Alternative Tax (MAT) paid in accordance with the tax laws in India, which gives rise to future economic benefits in the form of adjustment of future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax after the tax holiday period. Accordingly, MAT is recognised as an asset in the balance sheet when the asset can be measured reliably and it is probable that the future economic benefit associated with it will fructify.

Deferred tax expense or benefit is recognised on timing differences being the difference between taxable income and accounting income that originate in one period and is likely to reverse in one or more subsequent periods. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date.

Advance taxes and provisions for current income taxes are presented in the balance sheet after off-setting advance tax paid and income tax provision arising in the same tax jurisdiction for relevant tax paying units and where the Company is able to and intends to settle the asset and liability on a net basis.

The Company offsets deferred tax assets and deferred tax liabilities if it has a legally enforceable right and these relate to taxes on income levied by the same governing taxation laws.

m Provisions, Contingent liabilities and Contingent assets

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits and compensated absences) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognised in the financial statements. A contingent asset is neither recognised nor disclosed in the financial statements.

As per our report of even date



For, M/s. R B GOHIL & Co.
Chartered Accountants
Firm's Registration No.



CA Raghubha B. Gohil
Partner
Membership No. 104997
UDIN: 26104997KGILKR5984
Place: JAMNAGAR
Date: 07-05-2026

For and on behalf of the Board of
GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Sucheta D Jani
Director
DIN - 065022321

Hetal Thakkar
Director and CFO
DIN - 10756299

Place: Ahmedabad
Date: 07-05-2026



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India

**Email: investor@globalhospital.co.in;
Website: www.globalhospital.co.in**

Tel No.: +91-7211104280